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A Novel Elvitegravir Nanoformulation for Drug Delivery Across the Blood-Brain
Barrier to Suppress HIV-1 in Macrophages and Microglia
Abstract
Over the last two decades, the use of antiretroviral therapy (ART) has remarkably decreased the morbidity
associated with HIV-1 infection. However, the prevalence of HIV-1-associated neurocognitive disorders
(HAND) is still increasing. The appearance and persistence of HAND are partially due to the entry of
HIV-1-infected monocytes into the brain. Within the central nervous system (CNS), HIV-1-infected
macrophages and microglia serve as the major viral reservoirs and provide active viral replication even
when systemic viral suppression has been achieved by ART. Efficient viral suppression of CNS
macrophages and microglia is important for an effective HIV-1 treatment in the brain. The primary
hindrance to the treatment of HAND is mainly contributed by the inability of antiretrovirals (ARVs) to cross
the blood-brain barrier (BBB) after the systemic administration. Conventional regimens of ARVs are not
sufficient to penetrate the BBB or improve outcomes in HAND. Thus, there is a need for novel treatment
regimens that cross the BBB and deliver therapeutic ARVs into the CNS to suppress the HIV-1 replication
in these viral reservoirs. Our objective in this study was to improve the efficacy of ART in CNS HIV-1
reservoirs, specifically in macrophages and microglia. Our central hypothesis was that the selected ARV,
elvitegravir (EVG), in nanoformulation would have increased transmigration across the BBB, as well as
increased drug uptake in macrophages and microglia after crossing the BBB, leading to increased
antiviral activity in macrophages and microglia, relative to the native drug. This study was expected to
provide an optimized treatment strategy that has potential for therapeutic interventions in reducing
HAND.In this study, poly (lactic-co-glycolic acid) (PLGA)-based elvitegravir nanoparticles (PLGA-EVG NPs)
were prepared by nano-precipitation. Firstly, we analyzed the physicochemical properties of PLGA-EVG
NPs using transmission electron microscopy, dynamic light scattering (DLS), and Fourier-transform
infrared spectroscopy (FTIR). We measured cellular uptake of PLGA NPs by fluorescence microscopy and
flow cytometry. We also measured the intracellular drug concentration and viral replication in
HIV-1-infected macrophages by using LC-MS/MS and p24 ELISA, respectively. The PLGA-E
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ABSTRACT
Over the last two decades, the use of antiretroviral therapy (ART) has remarkably
decreased the morbidity associated with HIV-1 infection. However, the prevalence of
HIV-1-associated neurocognitive disorders (HAND) is still increasing. The appearance
and persistence of HAND are partially due to the entry of HIV-1-infected monocytes into
the brain. Within the central nervous system (CNS), HIV-1-infected macrophages and
microglia serve as the major viral reservoirs and provide active viral replication even
when systemic viral suppression has been achieved by ART. Efficient viral suppression
of CNS macrophages and microglia is important for an effective HIV-1 treatment in the
brain. The primary hindrance to the treatment of HAND is mainly contributed by the
inability of antiretrovirals (ARVs) to cross the blood-brain barrier (BBB) after the
systemic administration. Conventional regimens of ARVs are not sufficient to penetrate
the BBB or improve outcomes in HAND. Thus, there is a need for novel treatment
regimens that cross the BBB and deliver therapeutic ARVs into the CNS to suppress the
HIV-1 replication in these viral reservoirs.
Our objective in this study was to improve the efficacy of ART in CNS HIV-1
reservoirs, specifically in macrophages and microglia. Our central hypothesis was that the
selected ARV, elvitegravir (EVG), in nanoformulation would have increased
transmigration across the BBB, as well as increased drug uptake in macrophages and
microglia after crossing the BBB, leading to increased antiviral activity in macrophages
and microglia, relative to the native drug. This study was expected to provide an
optimized treatment strategy that has potential for therapeutic interventions in reducing
HAND.
In this study, poly (lactic-co-glycolic acid) (PLGA)-based elvitegravir
nanoparticles (PLGA-EVG NPs) were prepared by nano-precipitation. Firstly, we
analyzed the physicochemical properties of PLGA-EVG NPs using transmission electron
microscopy, dynamic light scattering (DLS), and Fourier-transform infrared spectroscopy
(FTIR). We measured cellular uptake of PLGA NPs by fluorescence microscopy and
flow cytometry. We also measured the intracellular drug concentration and viral
replication in HIV-1-infected macrophages by using LC-MS/MS and p24 ELISA,
respectively. The PLGA-EVG NPs showed an average particle size of ~47 nm from
transmission electron microscopy and a zeta potential of - 6.74 mV from DLS. These
PLGA NPs demonstrated a time- and concentration-dependent uptakes in monocytes.
PLGA-EVG NPs showed a ~2 times higher intracellular internalization of EVG than the
native drug in HIV-1-infected monocytic cell line. PLGA-EVG NPs also demonstrated
superior viral suppression to native drug for a prolonged period of time in human primary
monocyte-derived macrophages.
Secondly, we quantified the stability, human serum interaction, hemocompatibility, cyto-compatibility, and cellular internalization of the PLGA-EVG NPs.
The stability of PLGA NPs was assessed by measurement of particle size and zeta
potential of NPs under different storage conditions. The human serum interaction with
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NPs was assessed using FTIR, DLS, and sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) analysis. The biocompatibility of PLGA-EVG NPs was
studied with red blood cells (RBCs), macrophages, and microglia. We also studied the
endocytosis pathway and the sub-cellular localization of PLGA-NPs in macrophages and
microglia using endocytosis inhibitors and sub-cellular localization markers. These
characterizations suggest a favorable safety and stability profile of EVG nanoformulation
for use as a potential CNS delivery strategy. PLGA NPs were stable at room temperature
for at least a week and at 4 °C and -20 °C for at least 30 days with no change in size or
zeta potential. The PLGA-EVG NPs also showed a good biocompatibility with RBCs,
macrophages, and microglia. Human serum protein binding occurs on PLGA NPs with
upon incubation with human serum. The protein corona formed on PLGA NPs did not
significantly alter the particle size, hemocompatibility, or biocompatibility of PLGAEVG NP to human primary monocyte-derived macrophages and microglia. The
internalization of PLGA NPs in macrophages involves to a combination of endocytosis
pathways, while the main internalization of PLGA NPs in microglia occurred through
caveolae-/clathrin-mediated endocytosis. PLGA NPs can escape from endo-lysosomal
compartments and deliver the therapeutics to the cells efficiently.
Thirdly, we assessed the ability of PLGA-EVG NPs to cross the BBB and
suppress the HIV-1 replication in macrophage and/or microglial cells. The penetration of
EVG native drug /nanoformulation was determined using an in vitro BBB model and
validated with immunodeficient NSG mice. The efficacy of HIV-1 suppression in the
CNS was assessed using an in vitro BBB model utilizing HIV-1-infected human primary
monocyte-derived macrophages and microglia and validated with an HIV-1 encephalitic
(HIVE) mouse model. Compared with EVG native drug, the PLGA-EVG NPs
demonstrated improved BBB penetration in both in vitro and in vivo systems. Most
importantly, the PLGA-EVG NPs were able to show enhanced HIV-1 suppression in
HIV-1-infected human monocyte-derived macrophages and monocyte-derived microglia
after crossing the BBB, without altering BBB integrity. PLGA-EVG NPs also showed a
trend of decreasing CNS HIV-1 viral load in HIV-1-infected mice. Overall, this is an
innovative and optimized treatment strategy that has a potential for therapeutic
interventions in reducing HAND.
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CHAPTER 1.

INTRODUCTION

Introduction of HIV-1-Associated Neurocognitive Disorder (HAND)
In the past three decades, the introduction of antiretroviral therapy (ART) has led
to significant advances in the effectively management of HIV-1/AIDS [1]. However, the
prevalence of HIV-1-associated neurocognitive disorders (HAND) is still a major
concern, especially in the aging population [2]. Around 15-55% of HIV-1-infected
individuals are estimated to have HAND in the ART era, which remains the same
proportion as was reported prior to the widespread use of ART [3]. Although HIV-1associated dementia, the most severe form of HAND, is rare in developed countries due
to the use of ART, the incidence of asymptomatic neurocognitive impairment and minor
neurocognitive disorders remains unresolved [2]. The appearance and persistence of
HAND are mainly due to the entry of HIV-1 virus into the brain via the “Trojan horse”
mechanism through infected monocytes and macrophages [4, 5]. Monocytes and
macrophages can be infected by HIV-1 and can function as viral reservoirs because they
are capable of surviving with HIV-1 infection for an extended period of time [6]. These
HIV-1-infected monocytes/macrophages infiltrate the brain and spread the virus to
resident macrophages and microglia in the central nervous system (CNS) [7]. Further,
HIV-1 actively replicates in macrophages and microglia, providing persistent viral
replication in the brain [8, 9]. Since macrophages and microglia are located in the brain
parenchyma where neurons and glia connect extensively, HIV-1 has significant
opportunity to interact with neurons and uninfected glial cells [10]. Although neurons are
not directly infected by HIV-1 virus, active replication of HIV-1 in infected macrophages
and microglia produces toxic components, including viral proteins and inflammatory
cytokines and chemokines, which damage neurons and ultimately cause HAND [11, 12].
Individuals with HAND commonly show characteristics of dysfunctional and impaired
judgment, memory, multitasking, and attention [13]. Additionally, HIV-1 infection in the
brain affects not only cognitive functioning but also the opportunity for HIV-1
eradication [2]. The brain can serve as a viral reservoir for the production of HIV-1, and
provide active viral replication even when systemic viral suppression has been achieved
[14]. Currently, ART is the best option for delaying or preventing HIV-1-associated
disease progression [15]. However, due to the inability of antiretroviral drugs (ARVs) to
efficiently cross the blood-brain barrier (BBB) following systemic administration, ART is
still not clinically applicable for the treatment of HAND [2]. Thus, there is a need for
novel treatment regimens that cross the BBB and deliver therapeutics into the brain to
suppress viral replication in CNS cells. Discovering a new delivery system to maximize
the treatment outcomes of HAND has become an important research avenue in HIV-1
therapy.
Summary and Limitations of Current Treatment Strategies for HAND
In 1987, the United States (US) Food and Drug Administration (FDA) licensed
the first ARV zidovudine (also known as azidothymidine) [16]. Zidovudine works by
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inhibiting reverse transcriptase enzyme of HIV-1, slowing the replication of the virus and
the progression of the disease. In the last three decades, ART has made a significant
contribution to the reduction in HIV/AIDS-related death and improved quality of life for
people living with HIV/AIDS [17]. In 2018, there were more than 30 ARVs approved for
the treatment of HIV-1 in the US [18]. ARVs are classified into six groups according to
the mechanism of action: nucleotide reverse transcriptase inhibitors (NRTIs), nonnucleotide reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion
inhibitors (FIs), entry inhibitors (also known as CCR5 antagonists), and integrase strand
transfer inhibitors (INSTIs) [19]. ARVs can be used either as a single-drug regimen or a
combination of 3-4 drugs [20]. In most cases, in order to achieve highest efficacy, ARVs
are used in combination regimens that can attack multiple stages of the HIV-1 life cycle,
and subsequently slow the disease progression.
However, ARVs are not used as a specific treatment strategy for HAND. Many
ARVs have restricted entry into the CNS across the BBB after systemic administration
[21]. The BBB includes endothelial cells, pericytes, perivascular astrocytes, and tight
junctions, and forms an almost impermeable cellular barrier that restricts the free
diffusion of compounds into the CNS [22, 23]. In addition to the physical barrier, the
poor drug penetration is partly due to the active efflux mediated by membrane-associated
transporters located at the BBB. In particular, ATP-binding cassette (ABC) membraneassociated transporters, including P-glycoprotein (P-gp), breast cancer resistance protein
(BCRP), and multidrug resistance associated protein (MRP1) are significantly expressed
at the BBB [24]. As a result, the BBB only selectively transports molecules such as
certain amino acids, sugars, and hydrophilic molecules (e.g. oxygen and carbon dioxide)
into the brain. In addition, co-administration of ARVs with strong CYP3A4 inhibitors
such as cobicistat (cobi) and ritonavir (RTV) has been used to enhance the efficacy of
some ART regimens [25]. However, most ARVs show limited CNS penetration relative
to plasma drug concentration even with ritonavir (RTV) boosting [22, 26]. For example,
RTV boosting is capable of increasing indinavir plasma level significantly but not
cerebrospinal fluid (CSF) indinavir concentration [26]. When boosted with RTV,
atazanavir and lopinavir reach therapeutic concentrations in plasma, but remain
undetectable in CSF [22]. Previous clinical studies have demonstrated that the CNS
penetration-effectiveness (CPE) score of ARVs is correlated with the inhibition of HIV-1
replication in the CNS and superior cognitive performance in HIV-1-positive patients
[27, 28]. While several NRTIs and NNRTIs such as zidovudine and efavirenz showed
good CPE scores that penetrate the CNS well, high CNS concentrations of those ARVs
are neurotoxic and are potentially associated with the development of HAND [22]. Thus,
to achieve neurological benefit, the ideal therapeutic agent should achieve optimal CNS
penetration with minimal neurotoxicity.
Other than treating HAND through viral suppression, researchers are searching
for adjunctive therapies to treat the neurological and psychological secondary symptoms,
using anti-depressants, anti-psychotics, and anti-anxiety drugs [29]. Several
neuroprotective agents including memantine, selegiline, sodium valproate, paroxetine,
and fluconazole have been investigated as potential adjunctive therapies for patients with
HAND [29, 30]. However, prior trials of adjunctive therapies have not consistently
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shown clinical benefit in cognitive improvement in HAND patients [30]. Additionally,
the CNS can still serve as a latent HIV-1 reservoir with adjunctive therapies because
those drugs do not reduce viral replication and treat the root cause of HAND [30].
Specific developments in therapeutic agents that cross the BBB and suppress viral
replication are needed for the treatment of HIV-1 in the CNS.
Approaches of Antiretrovirals (ARVs) to Cross the Blood-Brain Barrier (BBB)
Several approaches, such as blocking ATP-binding cassette (ABC) transporters,
BBB opening strategy, prodrug therapy, and nanoparticle-based drug delivery, have been
employed to improve the penetration of ARVs [31]. Most ARVs, especially PIs, are ABC
transporter substrates and have limited brain penetration due to efflux transportation [31].
Using LY-335979, a P-gp inhibitor, to downregulate the P-gp expression increased the
brain concentrations of nelfinavir, amprenavir, indinavir, and saquinavir up to 37-fold,
while only modestly increased plasma drug levels, causing an increase in brain-plasma
ratios from 14-fold to 17-fold in mdr1a (+/+) mice [32]. Other studies have also shown
similar results with saquinavir and indinavir using P-gp inhibitors (quinidine and
GF120918) and an MRP1 inhibitor (MK571) in in vitro BBB models and in vivo mice
models [33, 34]. Although blocking ABC transporters may significantly improve drug
concentrations in the brain, this method is not clinically achievable as a treatment
approach for HAND because the inhibition of ABC transporters in other organs may
cause serious drug-drug interactions [31]. Another approach to increasing drug
penetration to the brain is the “BBB opening” approach. Opening the BBB can be
achieved by using a hyper-osmotic solution to shrink the endothelial cells or using certain
cytotoxic agents to disrupt the BBB tight junctions [35, 36]. However, opening the tight
junctions of the BBB is not recommended because it may also allow the entry of the virus
and other contaminants into the brain [31]. Development of prodrugs of ARVs to increase
their capacity to penetrate the BBB is another potential delivery approach [31]. Prodrugs
can be synthesized with sufficient lipophilicity to allow them to cross the endothelial cell
membrane and release the parent ARVs into the brain. Tenofovir disoproxil fumarate, a
prodrug of tenofovir, has shown the capability of crossing the blood-CSF barrier to reach
the HIV-1 infected perivascular and meningeal macrophages. Unfortunately, it was not
able to reach the deep brain, so there was no drug accumulation within HIV-1-infected
microglia [37]. Since prodrugs are considered to be a separate chemical entity, the
approval process for prodrugs is as complicated and difficult as for the parent molecule,
[31]. Developing prodrugs as a delivery approach needs a full evaluation of toxicity, cost,
and efficacy.
Compared with other CNS delivery approaches, nanoparticle (NP)-based drug
delivery approaches are an attractive option for the treatment of HAND [38]. NP-based
formulations are a colloidal system that made of polymers, lipids, or a combination of
both [39]. A therapeutic agent is either encapsulated in the core of the colloid matrix or
adsorbed entrapped on the surface of the particle. Because of their colloidal structure, an
NP-based drug delivery system can protect ARVs from efflux transporters and both
enzymatic and hydrolytic degradations, with a potential for controlled release [40]. NPs
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can cross the BBB through membrane transcytosis and effectively deliver the therapeutic
molecule to the CNS. Thus, a therapeutic molecule can be loaded on a nanoparticle which
has good interactions with the endothelial cells at the BBB and increases the drug’s
distribution throughout the brain [39].
NP-Based Drug Delivery for HAND
NPs that have been studied for brain delivery mainly include polymeric NPs such
as poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(D, L-lactide-co-glycolide)
(PLGA), and poly(butyl-cyanoacrylate) (PBCA) NPs [41, 42]; magnetic NPs (MNPs)
composed of an iron oxide core [42]; lipid-based nanoformulation such as solid lipid
nanoparticles (SLN) and liposomes; and micelle-based nanoformulations such as
Pluronic micelles [31]. As a proof-of-concept, preclinical studies have used NP-based
delivery systems for transport of ARVs across the BBB to suppress HIV-1 in the CNS
(Table 1-1).
Polymeric NPs
Since polymeric NPs are not only easily prepared and stored, but also highly
biocompatible and biodegradable in nature, they have been extensively studied for
delivery of therapeutics for cancer [43-46] and HIV-1 [47-50]. Several groups have
demonstrated the capability of polymeric NPs to deliver ARVs to the brain for the
treatment of HAND. Kou et al. have investigated the transmigration of ARVs including
stavudine, delavirdine, and saquinavir across an in vitro BBB by using PBCA NPs and
methylmethacrylate-sulfopropylmethacrylate (MMA-SPM) NPs [51]. The permeability
of those selected ARVs across human brain microvascular endothelial cells (HBMEC)
can be improved by 12- to 16-fold with PBCA NPs, and 3- to 7-fold with MMA-SPM
NPs. They also observed that a decrease in the BBB permeability is associated with an
increase in the particle size of NPs for these three ARVs. The same group further
modified the surface of the MMA-SPM NPs with a synthetic linear pseudopeptide, RMP7, for targeted delivery of stavudine, delavirdine, and saquinavir across the BBB [52]. In
this study, they used a polymerization initiator, ammonium persulfate, to generate
uniform and spherical RMP-7-MMA-SPM NPs. They found that the RMP-7-conjugated
NPs were able to mediate the opening of the tight junctions and enhance endocytosis by
the BBB, improving the permeability of these three ARVs into the brain. They also
investigated the use of PBCA NPs and MMA-SPM NPs with other ARVs such as
zidovudine and lamivudine [53]. Using the bovine brain endothelial cell line BBMEC as
an in vitro model of the BBB, PBCA NPs were able to improve the BBB permeability of
zidovudine and lamivudine by up to 20 and 18 folds, respectively. MMA-SPM NPs were
able to improve the BBB permeability of zidovudine and lamivudine by 1 fold [53]. In
addition, Mainardes et al developed PLA NPs and PLA-polyethylene glycol (PEG) blend
NPs containing zidovudine [54]. The PLA NPs and PLA-PEG NPs showed mean
diameters of 265.8 nm and 328.1 nm, respectively. Although they did not study the brain
permeability of the NPs directly, they showed the PLA-PEG blend NPs have the capacity
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Table 1-1.

Summary of NPs of ARVs used for CNS delivery.

NP type

Particle materials

ARVs

Polymeric
NPs

PBCA

Polymeric
NPs

MMA-SPM

Polymeric
NPs

RMP-7/MMASPM

Polymeric
NPs
Polymeric
NPs
Polymeric
NPs
Polymeric
NPs
Magnetic
NPs

PBCA

PLA

stavudine,
delavirdine,
saquinavir
stavudine,
delavirdine,
saquinavir
stavudine,
delavirdine,
saquinavir
zidovudine,
lamivudine
zidovudine,
lamivudine
zidovudine

PLA-PEG

zidovudine

Fe3O4,
phosphatidyl
choline,
cholesterol
Fe3O4, vorinostat

Magnetic
NPs

MMA-SPM

Size (nm)

Tested model

Ref.

184

Improvement of BBB
transmigration (compared with
native drug)
↑ 12-16 fold

HBMEC cells

[51]

68

↑ 3-7 fold

HBMEC cells

[51]

50

-

HBMEC cells

[52]

150

BBMEC cells

[53]

25

↑ 20 fold,
↑ 18 fold
↑ 1 fold

BBMEC cells

[53]

265.8

-

-

[54]

328.1

-

-

[54]

azidothymidine 150

↑ 3 fold

BMVEC cells

[55]

tenofovir

↑ 2 fold

HBMEC cells

[56]

10±3
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Table 1-1.

(Continued).

NP type

Particle materials

ARVs

Magnetic
NPs

Fe3O4,
PEG, transferrin
antibody,
phophatidyl
choline,
cholesterol
CoFe2O4, BaTiO3

nelfinavir,
tenofovir

Magnetic
NPs
Magnetic
NPs
Lipidbased NPs
Lipidbased NPs
Micellebased NPs

Size (nm)

Improvement of BBB
transmigration (compared with
native drug)
↑ 50-100% (compared to MNPs
without transferrin conjugation)

Tested model

Ref.

HBMEC cells

[57]
[58]

azidothymidine 19-31

↑ 3 fold

HBMEC cells

[59]

Fe3O4, Au,
DPPC, cholesterol,
PEG
hydrogenated
castor oil
flaxseed oil

tenofovir
disoproxil
fumarate
darunavir

~100

↑ 1 fold

CHME-5 cells [60]

200

↑ 3 fold

saquinavir

100-200

↑ 5 fold

Pluronic 407

dolutegravir

300-400

No neurotoxicity

male Wistar
rats
male Balb/c
mice
male Balb/c
mice

410±15

[61,
62]
[63]
[64]

Notes: PBCS- polybutylcyanoacrylate, MMA-SPM- methyl methacrylate–sulfopropyl methacrylate, PLA- poly (lactic acid), DPPC1,2-dipalmitoyl-sn-glycero-3-phosphocholine, PEG- polyethylene glycol. – Data not available.
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to avoid the phagocytosis, staying in the systemic circulation for longer time, and can be
used as a potential delivery method to transport zidovudine into the brain.
Magnetic NPs
In order to deliver therapeutics to the brain more specifically, MNPs which can be
controlled by an external magnetic field are used [65]. MNPs transport through the BBB
followed the external magnetic force, which allows the control of movement and speed.
Saiyed et al. from the Nair group developed a MNPs of an NRTI (azidothymidine)
encapsulated into liposomes made with a mixture of phosphatidyl choline and cholesterol
[55]. These magnetic liposomes can be taken up by monocytes, which further enhances
the BBB transmigration. These magnetic liposomes showed 3-fold higher transmigration
across an in vitro BBB model, compared to the free drug, following application of an
external magnetic field. The magnetic liposomes of azidothymidine also showed slightly
lower p24 antigen production then free drug, when treated to HIV-1-infected human
peripheral blood mononuclear cells (PBMCs) [55]. Jayant et al. from the same group also
demonstrated the development of a layer-by-layer (LbL) MNP to achieve sustained drug
release in the brain [56]. The magnetic LbL NP was made with an HIV-1 NRTI
(tenofovir) and a latency-breaking agent (vorinostat). The magnetic LbL NP showed a
37.95% BBB transmigration and 33% p24 suppression on primary astrocytes in vitro
after 5 days of the initial dose [56].
The same group also attempted to encapsulate MNPs into PEGylated liposomes
conjugated with anti-transferrin antibody to target transferrin receptor-mediated
transportation through the BBB [57]. These transferrin-targeted MNPs showed a 50100% increase in drug transmigration across the in vitro BBB compared with MNPs
without transferrin. A recent study from the Nair group combined the use of LbL MNPs
and transferrin-targeted MNPs, developing a transferrin-conjugated LbL MNP of
nelfinavir and tenofovir [58]. The transferrin-conjugated LbL MNPs were able to
transmigrate ~15% of MNPs across the in vitro BBB. These MNPs provided a 10-day
sustained release profile and continually suppressed HIV-1 virus up to ~50% in HIV-1infected human astrocytes. In addition, Nair et al. developed a magneto-electric
nanoparticle (MENPs) to exhibit both magnetic and electric property of the NP for the
delivery of azidothymidine [59]. Because of the dual effect from the magnetic field and
the electric force, the movement and drug release of MENPs can be remotely controlled
by manipulating those fields. These MENPs were enabled to transmigrate ~ 40%
azidothymidine across the BBB in the in vitro BBB within 6 hours, while free drug only
showed ~10% transmigration. A higher HIV-1 p24 viral suppression was also observed
in PBMCs by using the MENPs with no cytotoxicity.
Other than the Nair group, Tomitaka et al. developed magneto-plasmonic
liposomes (MPLs) of tenofovir disoproxil fumarate [60]. The MPLs are made of sodium
citrate coated MNPs, coated with Au and polyethylene glycol, then encapsulated into a
liposome that was made of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and
cholesterol. One-fold higher transmigration of MPLs was observed in the presence of an
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external magnetic field and the MPLs also provided a greater p24 reduction compared
with free tenofovir disoproxil fumarate.
Lipid-Based NPs
Lipid-based NPs are made of a wide range of biological lipids and have shown
potential for delivery of ARVs to the CNS [31]. Due to their lipophilic structures, lipidbased NPs naturally show high affinity for the BBB. Desai et al. developed an SLN of
the HIV-1 PI darunavir, which enhanced the oral bioavailability by ~4-fold in
comparison to native darunavir obtained from the rats’ pharmacokinetics data [61]. The
authors have clearly demonstrated both advantages of SLN and of active targeting of the
drugs to reach the HIV reservoir [61, 62]. They showed that the improvement in oral
bioavailability could be attributed to darunavir entrapping in the lipid matrix, resulting in
enhanced lymphatic uptake of NPs and absorption over the native drug [61]. The same
group also developed NPs loaded with darunavir and grafted the surface with a peptide
sequence (CARRPKFYRAPYVKNHPNVWG) that has an affinity for CD4 receptors on
the HIV host cells [62]. The authors reported an enhancement in transport of SLNs
loaded with darunavir in Caco-2 cells, which mimics the gastrointestinal membrane, by
4-fold in contrast to free darunavir, due to increased endocytosis. Further, these SLNs
were able to penetrate the BBB and have 3-fold increased accumulation in the brain in
comparison to native darunavir suspension [62]. In addition, Vyas et al. prepared a
flaxseed oil-based nanoemulsion of saquinavir for brain delivery [63]. The size of the
saquinavir-containing nanoemulsion is in the range of 100-200 nm. When dosed orally,
the nanoemulsion showed a 3-fold higher saquinavir systemic exposure compared with
native drug. Importantly, the nanoemulsion significantly altered the drug distribution in
the brain. The maximum concentration of saquinavir was found to be 5-fold higher in the
brain, and the area under the curve (AUC) of the drug was found to be 3-fold higher in
the male Balb/c mice brain.
Micelle-Based NPs
A micelle-based NP is an amphiphilic, self-assembling polymeric NP which has a
hydrophobic core to encapsulate poor water-soluble drugs [66]. Due to their amphiphilic
structure, micelle-based NPs have a hydrophilic exterior surface that provides optimized
aqueous solubility. For example, Montenegro-Burke et al. from the Gendelman group
demonstrated the use of Pluronic micelles to achieve a long-acting slow release of an
ARV, dolutegravir [64]. They used Pluronic 407 to prepare a P407-dolutegravir micelles
with particle size of 300-400 nm. They observed a large quantity of oxidative stressrelated metabolites in brain subregions when using the native doltegravir, suggesting the
potential neurotoxicity and incompatibility of doltegravir as a therapeutic method for the
intervention of HAND. However, negligible oxidative stress-related metabolites were
observed when doltegravir is encapsulated in the Pluronic 407 NP. This study
demonstrated the potential use of micelle-based NPs to minimize the neurotoxicity of
doltegravir for the treatment of HIV-1 in the CNS.
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In summary, although NP-based delivery systems of ARVs for CNS delivery are
still limited to preclinical studies, recent studies have shown the potential of NPs to cross
the BBB and combat HIV-1 infection in the CNS [31]. Size, charge, and surface
modification of NPs all can contribute to successful CNS delivery. NPs with a size
smaller than 200 nm have a better chance to cross the BBB via transcytosis through
clathrin-mediated endocytosis. Since the endothelial cell layer is negatively charged,
positively charged NPs can enter the BBB through adsorptive transcytosis, which is
easier than neutral or negatively charged NPs. On the other hand, neutral and negatively
charged NPs also have benefits because of their reduced protein adsorption, leading to a
longer circulation period. NPs can also be modified with ligands to target transport- or
receptor-mediated transcytosis, such as via albumin transporters and glucose transporter 1
(GLUT1) [31]. Overall, NP-based delivery systems are likely to provide a new approach
for delivery of ARVs for HAND therapy. Since NP-based delivery systems are a novel
delivery method, in order to move forward toward clinical use, comprehensive toxicity
and safety assessments of NPs need to be performed, including assessment of long-term
adverse reactions, neurotoxicity, accumulation of nanomaterials, and their efficacy after
release inside the CNS.
Drug Delivery Strategy Involving PLGA-NPs and Elvitegravir (EVG)
HIV-1 enters brain via HIV-1-infected monocytes and macrophages and spreads
the virus in CNS cells especially perivascular macrophages and microglia [8, 9, 67]. Due
to the active replication of HIV-1 in these CNS reservoirs, toxic components including
viral proteins and inflammatory cytokines and chemokines are produced, leading to
immune activation, inflammation, and neuronal damage [11, 12]. In our study, we
selected elvitegravir (EVG) as our therapeutic molecules, which is an FDA-approved
INSTI, and is part of the first line ART regimen for the newly infected HIV-1 populations
in the USA [68]. Mohideen et al. formulated EVG into PLA NPs for protection against
HIV-1 [69]. The surface of this PLA NPs was formed with hyperbranched polyglycerols
(HPG) to create bio-adhensive NPs. EVG showed a prolonged retention on C57BL/6
mice vaginal lumen compared with free drug. Moreover, Mandel et al. from the Destache
group developed a PLGA-based NP containing EVG and tenofovir alafenamide for
subcutaneous delivery as a prevention strategy against HIV [70]. The size of NP was
190.2 nm with zeta potential of -19.2 mV. A detectable drug level was found from with
the NP group for 14 days, while the free drug showed a detectable drug level for 72 h.
This EVG NPs were able to protect the mice with 100% and 60% of uninfected rate on
day 4 and day 14, respectively, after HIV challenge. The half-life of EVG was also
improved from 11 h to 3.3 days in humanized CD34+ NSG mice [71].
We selected EVG as the therapeutic molecule in our nanoformulation because
EVG has a better safety profile than other classes of ARVs [72], which would make it
more appropriate to use as a CNS therapy approach. EVG has limited BBB penetration,
showed as low as ~0.3% CSF-plasma drug concentration ratio in HIV-infected
individuals [73]. To improve efficacy of EVG, we decided to encapsulate the drug into a
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NP formulation to increase its transmigration across the BBB, and increased drug uptake
in macrophages and microglia after entry into the CNS. With regards to NPs, we selected
PLGA-NP delivery system because it is a biodegradable and FDA-approved material for
human clinical applications [74]. PLGA NPs have been shown to have improved delivery
of therapeutic molecules across the BBB with safe and minimal/tolerable off-site toxicity
to cells [75]. PLGA NPs also have been shown to have the ability to encapsulate multiple
drugs, including ART drugs, which is important for treating HIV-1, as single drug
regimen for HIV-1 is not sufficient to effectively suppress HIV-1 [70]. A schematic
graph of the overall strategy for this study is showed in Figure 1-1.

Figure 1-1. The development of HAND and the use of EVG nanoformulation
across the BBB to suppress the CNS HIV-1 viral replication.
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CHAPTER 2.

SCIENTIFIC PREMISE, HYPOTHESIS, OBJECTIVE AND
SPECIFIC AIMS
Scientific Premise

The scientific premise of this project is derived from literature reports and our
own studies: 1) HIV-1 can infiltrate the brain through monocytes and actively replicate in
brain macrophage and microglia [8, 9, 67]. 2) At least 25% of ART-treated HIV-1
patients developed one or more neurological syndromes [76]. 3) HIV-1 in the brain is
difficult to eliminate by current ART, primarily as a result of their suboptimal ARV
concentrations [21]. 4) The suboptimal drug concentrations in the brain can be explained
by the inability of ARVs to cross the BBB after systemic administration [21]. 5) The drug
efflux transporters P-gp and MRP1, and the drug-metabolizing enzyme cytochrome p450
3A4 (CYP3A4), are significantly expressed in both macrophages and microglia, making
it more difficult to maintain therapeutic drug levels in these cells [77-79]. 6) The
literature shows that NPs are generally taken up by cells more efficiently than native drug
are [38]. 7) The brain permeability of a drug can be optimized by NP-based drug delivery
systems [38]. 8) Due to the rapid in vivo degradation and the minimal possibility of NP
accumulation in the brain, NPs made with biocompatible polymers are suitable for brain
delivery [39]. 9) Poly(lactic-co-glycolic acid) (PLGA) is a biocompatible polyester that
can be converted into water and carbon dioxide via the tricarboxylic acid cycle and
eventually eliminated from the body [74]. The literature shows that poloxamer 188
coating can help PLGA NPs deliver therapeutics more efficiently into the brain [80].
Hypothesis and Objective
Our central hypothesis is that the selected ARV, elvitegravir (EVG), in a
poloxamer188-PLGA-based NP will have increased transmigration across the BBB, and
increased drug uptake in macrophages and microglia after crossing the BBB, leading to
increased antiviral activity in those cells, relative to the free drug. Our objective in this
study is to improve the viral suppression efficacy of EVG in CNS HIV-1 reservoirs,
especially macrophages and microglia, and to provide an optimized treatment strategy
that has a potential for therapeutic interventions in reducing HAND.
Clinical Significance and Impact
This project provides the basis of scientific knowledge and technical capability of
using a poloxamer188-PLGA-based NP as a new delivery modality for the effective
treatment of HIV-1 infection in viral reservoirs in the brain, such as macrophages and
microglia. This project demonstrates the potential use of NPs to provide a more favorable
drug pharmacokinetics, greater viral suppression efficacy, and a superior safety profile
when compared with free drug molecules. When the aims of this project are achieved, the
concepts, methods, technologies, and potential interventions related to the application of
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PLGA-based NP that target macrophages and microglia would provide a necessary base
for the effective treatment of HAND.
Specific Aims
Aim 1: Synthesize, Characterize, and Determine Pharmacokinetic Profile and
Efficacy of the PLGA-based NP for the Potential Use of Delivery EVG to
Macrophages
We will synthesize a poloxomar188-PLGA based NP (PLGA-NP) formulation
with EVG (PLGA-EVG NPs). We will analyze the physicochemical properties of PLGANPs using transmission electron microscopy [54], dynamic light scattering (DLS), and
Fourier-transform infrared spectroscopy (FTIR). We will measure the cellular uptake of
PLGA-NPs using flow cytometry. We will also measure the intracellular drug
concentration and viral replication in macrophages by using LC-MS/MS and p24 ELISA,
respectively. We will obtain the physicochemical properties and cellular internalization
of PLGA NPs to show their potential use of increasing drug concentrations in
macrophages through Aim 1.
Aim 2: Determine the Stability, Protein Corona, Biocompatibility, and Cellular
Internalization Pathway of PLGA-EVG NPs
We will identify the particle size and zeta potential of PLGA NPs under different
storage conditions. We will assess the human serum protein adsorption of PLGA NPs
using FTIR, DLS, and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE) analysis. We will identify the biocompatibility of PLGA-EVG NPs with red
blood cells (RBCs), macrophages, and microglia. We will also study the endocytosis
pathway and the sub-cellular localization of PLGA-NPs in macrophages and microglia
using endocytosis inhibitors and sub-cellular localization markers.
Aim 3: Assess the Ability of PLGA-EVG NPs to Cross the BBB and the
Improvement of Viral Suppression in HIV-1-Infected Macrophages and Microglia
after BBB Transmigration
We will perform transmigration assays of PLGA-NPs on both the in vitro BBB
model and in vivo mouse model. We will calculate the percentage of transendothelial
migration of EVG in EVG-loaded NPs and in free drug form. We will also assess viral
suppression in HIV-1-infected macrophages and microglia after crossing the BBB, and
we will also use an HIV-1 encephalitic (HIVE) mice model to validate the results.
The overall strategies for specific aims are showed in Figure 2-1.
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Figure 2-1. Overall strategies of developing PLGA-EVG NPs for drug delivery across the BBB to suppress HIV-1 in
macrophages and microglia.
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CHAPTER 3.

MATERIALS AND METHODS1

Chemicals and Reagents
Elvitegravir (EVG, E509000) was purchased from Toronto Research Chemicals
Inc. (Ontario, Canada). Poly(D,L-lactide-co-glycolide) (PLGA) (50:50 lactide-glycolide
ratio, Mw: 31,000–50,000, ester-terminated) was brought from Birmingham Polymers
(Pelham, AL). The following items were obtained from Sigma-Aldrich Co. (St. Louis,
MO): poloxamer 188 (pluronic F-68) (P1300, Mw: 8350), poly(vinyl alcohol) (PVA)
(363138, Mw: 30,000–70,000), poly(L-lysine) (PLL) (Mw: 30,000–70,000), coumarin-6
(442631), acetone (650501), nocodazole (M1404), cytochalasin-D (Cyto-D) (C8273),
chlorpromazine (CPZ) (C1240), monensin sodium salt (M5273), genistein (G6649),
methyl-β-cyclodextrin (Mβ-CD) (C4555), hexadimethrine bromide (polybrene) (107689),
MitoTrackerTM Deep Red (M22426), Texas RedTM Conjugate (T2875), CellLightTM Late
Endosomes-RFP (C10589), and Terg-a-zyme® enzyme detergent (Z273287). HPLC
grade acetonitrile (A955) and formic acid (85178), BD PrecisionGlide 25G needle (14826-49) and BD 1mL TB syringe (14-826-88) were obtained from Fisher Scientific
(Hampton, NH). Sterile phosphate-buffered saline was obtained from Gibco (Dublin,
Ireland). Ethylenediaminetetraacetic acid (EDTA) was purchased from Boston Bio
Products (Ashland, MA).
Dulbecco's Modified Eagle's Medium (DMEM) was obtained from American
Type Culture Collection (Manassas, VA, USA). Roswell Park Memorial Institute (RPMI)
1640 media and lymphocyte separation medium were bought from Corning Inc
(Tewksbury, MA). Fetal bovine serum (FBS) was obtained from Atlanta Biologicals, Inc.
(Atlanta, GA). Ammonium-chloride-potassium lysing buffer were obtained from Life
Technologies (Carlsbad, CA). L-glutamine and penicillin-streptomycin (P/S) were
purchased from Fisher Scientific. The human recombinant cytokines, including M-CSF,
GM-CSF, beta-nerve growth factor (NGF-β), and CCL2 used for macrophage/microglia
differentiation were purchased from PeproTech (Rocky Hill, NJ), Recombinant Human
IL-2 Protein was purchased from R&D Systems, Inc. (Minneapolis, MN). HIV-1 Ada
strain was obtained from the NIH AIDS Reagent Program (Germantown, MD).
RosetteSep enrichment cocktail was purchased from StemCell Technologies (Vancouver,
Canada). The p24 ELISA kit (801111) was purchased from ZeptoMetrix Corporation
(Buffalo, NY) to assess HIV-1 viral load in HIV-1-infected macrophages and microglia.
--------------------1
Portions of chapter reprinted from final submission with permission. Gong, Y., et al.
(2017). Novel elvitegravir nanoformulation approach to suppress the viral load in HIVinfected macrophages. Biochemistry and Biophysics Reports, 2017. 12: p. 214-219. DOI:
https://doi.org/10.1016/j.bbrep.2017.10.005 [81]. Portions of chapter reprinted from final
submission with open access permission. Gong, Y., et al. (2020) Novel elvitegravir
nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1
suppression in the CNS macrophages. Sci Rep 2020. 10, 3835. DOI:
https://doi.org/10.1038/s41598-020-60684-1 [82].
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Experimental Methods
Preparation of PLGA-EVG NPs
The PLGA-EVG NP formulation was prepared by nano-precipitation as described
in our previous study [83]. In brief, PLGA (45 mg) and EVG (4 mg) were dissolved in 4
mL of acetone to obtain PLGA-EVG uniform solution. This PLGA-EVG solution was
added dropwise into 10 mL of 1% PVA-aqueous solution on a magnetic stir plate at 400
rpm. After 3 hours, 10 mg of PLL was dissolved in 1 mL water, and 50 mg of pluronic
polymer F-68 was dissolved in 4 mL water. PLL and F-68 solutions were added to the
nanoparticle suspension and stirred at room temperature for ~24 hours to evaporate
acetone completely. The non-uniform and larger aggregates of PLGA, PLGA-EVG,
PVA, and PLL ingredients were removed by centrifugation at 1,000 rpm for 10 min. The
finer and uniform PLGA-EVG NP formulation was stored at 4 °C or -20 °C until further
use. A blank PLGA NP formulation was also prepared by using the same protocol
without EVG. The hypothetical single NP structure of PLGA-EVG is illustrated in
Figure 3-1. PLGA forms the core for holding the native drug EVG and the layers of PVA
and PLL were added to ensure better encapsulation efficiency of the EVG inside the NPs.
Pluronic F-68 (the PEO and PPO chains of F-68 polymer) was added to maintain a stable
formulation for therapeutic application.
Physiochemical Characterization of PLGA-EVG NPs
The average particle size and zeta potential of the prepared PLGA-EVG
nanoparticles were determined by dynamic light scattering (DLS) using a Zetasizer Nano
ZS (Malvern Instruments, Malvern, UK). The morphology of PLGA-EVG NPs was
confirmed by transmission electron microscope (TEM) (JEOL-2000EXl, Tokyo, Japan).
For the DLS measurement, 50 μL of freshly prepared 0.5 mg/mL PLGA-EVG NP was
diluted with distilled water and probe sonicated with ultrasonic homogenizer model 3000
(Biologics, Inc.; Cary NC) for 30 sec. Particle size measurements were performed in
water for 3 min at 25°C. The average of three measurements was recorded. Zeta potential
measurement was done in a similar manner, where the NP was diluted with PBS. The
zeta potential of NP formulation was also based on the average of 3 readings (each
reading = 30 runs). To study the morphology of NPs, 20 μL of the 0.5 mg/mL of PLGAEVG was carefully placed on the shiny side of the 200 mesh standard TEM grid
(Electron Microscopy Sciences, Hatfield, PA). Uranyl acetate solution (2%; w/v) was
used to stain the nanoparticles for achieving positive contrast under TEM. To remove
excess amount of formulation, a small piece of filter paper was used, and the grid was
allowed to air dry followed by imaging under the TEM system using a direct
magnification of 100,000x. To acquire the FTIR spectral data of formulation(s), samples
were lyophilized to obtain dry solid powder using a Labconco Freeze Dry System (-48°C
133 x 10-3 m Bar; Labconco; Kansas City, MO). FTIR spectra were obtained on the
Universal ATR sampling accessory plate using a Spectrum 100 FTIR spectrophotometer
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Figure 3-1.

A hypothetical structural representation of the PLGA-EVG NP.
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(Waltham, MA) for drug encapsulation. The samples were placed on the tip of the ATR
objective and spectra were obtained between 4000 and 650 cm-1.
In Vitro Drug Release
The in vitro drug release study was performed using a Float-A-Lyzer£ dialysis
bag with molecular weight cut-off of 8-10 kDa (Sigma-Aldrich Co. Z726508). A volume
of 1 mL PLGA-EVG NPs was enclosed in a dialysis bag and incubated in 30 mL cell
culture media at 37 °C under mild agitation in a Thermo Scientific water bath shaker
Percision SWB 15 at speed of 35 rpm. At 15, 30 min, and 1, 3, 6, 9, 12, 24 h, 500 μL
incubation media was withdrawn and kept at 4 °C for analyzing of EVG concentration
using LC-MS/MS. The same volume of fresh media was added to the incubation media
after each sampling.
Cellular Uptake of PLGA NPs in Monocytes
Cellular uptake of PLGA NPs were assessed by Accuri C6 Flow Cytometer
(Accuri Cytometer Inc, Ann Arbor, MI), and images were taken by EVOS® FL Imaging
System (AMF4300, Life Technologies; Carlsbad, CA). Monocytes (0.5×106) were
cultured in a 6-well plate and allowed to attach overnight. For this study, coumarin-6
(C6) dye was encapsulated in PLGA NPs in a similar manner as drug loading in PLGA
NPs as PLGA-EVG NPs. The particle size of C6 loaded PLGA was measured by DLS. In
this study, C6 dye was used to track, locate, and measure green fluorescence for semiquantitative and qualitative cellular uptake. Cells were treated with 5 μg/mL of PLGA-C6
at different time points (0.5, 1, 2, 3, 4 hours) and at different concentrations of C6 (0.5, 1,
2.5, 5, 10 μg/mL) for 3 hours. After the course of treatment, cells were washed with PBS,
trypsinized, and collected in phenol-red free medium. Then, semi-quantitative and
qualitative C6 uptake in PLGA NPs were assessed by using flow cytometry with the FL1
channel (488 excitation, blue laser, 530 ± 15 nm, FITC/GFP) and EVOS® FL Imaging
System [83].
Generation of Human Monocytes-Derived Macrophages and Monocytes-Derived
Microglia
Human monocytes-derived macrophages (MDM) and monocytes-derived
microglia (MMG) were differentiated from buffy coats that isolated from de-identified
human whole blood, which was obtained from Interstate Blood Bank Inc. (Memphis, TN)
upon approval from the Institutional Review Board (IRB, UTHSC) according to
previously published reports [84, 85]. Buffy coats were incubated with the RosetteSep
enrichment cocktail for 20 min to enrich the yield of peripheral blood mononuclear cells
(PBMCs). After 20 min incubation, the buffy coats were diluted with same volume of
PBS with 2% FBS and layered over the lymphocyte separation medium and centrifuged
for 20 min at 1200 g with acceleration of 1 and deceleration of 0. A white ring layer
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containing PBMCs formed in between the plasma and lymphocyte separation medium
were carefully collected. The collected PBMCs were washed with PBS with 2% FBS for
3 times to ensure the removal of lymphocyte separation medium. The cells were then
incubated with ammonium-chloride-potassium lysing buffer at 4ºC for 15 minutes to lyse
and remove red blood cells. PBMCs for MDM differentiation were collected and cultured
in RPMI media containing 10% human serum, 1% L-glutamine, and 5% penicillinstreptomycin. PBMCs for MMG differentiation were collected and cultured in RPMI
media containing 1% L-glutamine and 5% penicillin-streptomycin. After overnight
incubation, non-adherent cells were washed out with PBS. The adherent PBMCs were
used for the generation of MDM and MMG. M-CSF (50 ng/mL) was added to the MDM
flasks for macrophage differentiation and human recombinant cytokine mixture
containing M-CSF (10 ng/mL), GM-CSF (10 ng/mL), NGF-β (10 ng/mL), and CCL2
(100 ng/mL) were added to the MMG flasks for microglia differentiation. Mature MDM
were collected after 7-10 days differentiation. Mature MMG were collected after 14 days
of differentiation when they reached 70-80% confluence.
HIV-1 Infection of Macrophages and Microglia
For HIV-1 infection, mature MDM were collected after 7 days of differentiation,
followed by incubation with polybrene (2 μg/mL) and HIV-1 Ada strain (30 ng/1×106
cells) for HIV-1 infection in a 12-well plate with 3×105 cells/well. After overnight
incubation, MDM were washed twice with PBS to remove the polybrene and HIV-1 Ada
strain. The cells attached on the bottom of the well were considered as healthy primary
MDM with initial HIV-1 infection. IL-2 (10 ng/mL) was added to the culture media of
MDM to induce HIV-1 infection. Mature MMG were collected after 14 days of
differentiation when they reached 70-80% confluence. One T75 flask of MMG was
plated in one 12-well plate with an equal number of cells in each well. MMG were
incubated with polybrene (2 μg/mL) and HIV-1 Ada strain at 3 ng/well for HIV-1
infection. After overnight incubation, MMG were washed twice with PBS to remove the
polybrene and HIV-1 Ada strain. After 7-10 days of the initial HIV-1 infection, cell
culture media samples from MDM/MMG were collected to assess HIV-1 p24 level using
a p24 ELISA kit to confirm the HIV-1 infection.
Intracellular EVG Concentration and Viral Suppression of PLGA-EVG in HIV-1Infected Macrophages
Intracellular EVG concentration of PLGA-EVG was measured in HIV-1-infected
U937 cells (known as U1 cells) obtained from NIH AIDS Reagent Program. U1 cells
were grown in RPMI media supplemented with 1% L-glutamine, 10% FBS, and
penicillin-streptomycin solution and plated in a 12-well plate with 3×105 cells/well. The
cells were differentiated into macrophages using 100 nM phorbol 12-myristate 13-acetate
(PMA) for 72 hours. Differentiated cells were treated with EVG native drug at
physiological concentration (0.5 μg/mL), and PLGA-EVG NPs (0.5 μg/mL). The EVG
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concentration in cell lysates was determined over a period of 0.1, 0.15, 0.5, 1, 3, 9, 24,
48, and 72 hours by using LC-MS/MS.
Viral suppression of PLGA-EVG was performed on HIV-1-infected MDM. HIV1-infected MDM were plated in in a 12-well plate with 3×105 cells/well. MDM were
treated with acetonitrile, EVG dissolved in acetonitrile (0.5 μg/mL), PLGA-EVG NPs,
(0.5 μg/mL), and PLGA-Blank NPs for 10 days. Equal volume of acetonitrile and PLGABlank NPs were served as control for both EVG native drug and PLGA-EVG NPs. Fresh
media was added every three days to ensure cell viability. Cell culture media samples
were collected every 24 hours to assess HIV p24 production by p24 ELISA.
EVG Quantification Using LC-MS/MS
EVG was quantified using the LC-MS/MS method as described in our previous
report [86]. The LC-MS/MS system used was a liquid chromatography system (Shimadzu
Corp.; Kyoto, Japan) coupled to a tandem mass spectrometer (AB SCIEX, Triple Quad
5500; Framingham, MA). Acquisition was performed in multiple reaction monitoring
(MRM) mode, and the Analyst® software (AB Sciex, Foster City, CA) was used for data
acquisition and processing. For mass spectrometric analysis, an electrospray ionization
(ESI) source operating in positive mode was set with the following parameters: ion spray
(IS) voltage: 5500 V; curtain gas: 20 psi; ion source gas 1 (GS1) and ion source gas 2
(GS2): 50 psi; collision-activated dissociation (CAD) gas: 8 psi; source temperature: 400
°C. The selected Q1/Q3 (m/z) for EVG was 447.9/343.8 and for internal standard (IS)
ritonavir (RTV) is 721.3/296.1. The optimized collision energy (CE) and collision cell
exit potential (CXP) for EVG were 43 and 20 V, respectively, with declustering potential
(DP) of 100 V and entrance potential (EP) of 10 V, respectively. The optimized CE and
CXP for RTV were 27 and 29 V, respectively, with DP value set at 100 V and EP value
set at 10 V.
EVG standards and experimental samples were extracted by adding either 3 or 9
volumes of cold acetonitrile depend on the sample types, which contained 50 ng/mL RTV
as an internal standard (IS). The mixed solution was vortexed, centrifuged, and analyzed
using the LC-MS/MS. In order to reduce matrix effects, calibration curves were prepared
with blank media, cell lysate, plasma, or brain homogenate based on the sample types. A
6 μL aliquot of extracted samples was injected into an Xterra® MS C18 column (125Å,
3.5 μm, 4.6 mm X 50 mm; Waters, Milford) for separation. The mobile phase consisted
of (A) water with 0.1% formic acid and (B) acetonitrile with 0.1% formic acid (v/v) at a
flow rate of 1 mL/min. The gradient elution was as follows: 0-1.5 min, 50% B; 1.5-5.1
min, 60% B (v/v).
Stability Assay
We determined the particle size and zeta potential of PLGA NPs using DLS.
PLGA NPs were stored at room temperature, 4 °C, or -20 °C for a stability test. DLS
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analysis was performed on the room temperature sample for 7 days. The size and zeta
potential of PLGA NPs from 4 °C and -20 °C were measured on day 7, and an additional
measurement was performed on day 30 for the -20 °C sample. The particle size and zeta
potential of PLGA NPs in 1 mM HEPES buffer from pH 1 to pH 11 were measured to
investigate the alteration of PLGA NPs with this pH range.
Human Serum Protein Binding to PLGA NPs
To measure the weight of PLGA NPs, PLGA NP samples were lyophilized to
obtain dry solid powder using a Labconco Freeze Dry System. The lyophilized NP
samples were weighted and calculated the weight of NPs as per μL. Three hundred
microgram of PLGA NPs were incubated with 600 μL of 1-50 wt./v.% human serum
(HS) and stirred at room temperature for 3 hours. The HS-bound PLGA NPs were
obtained by a centrifugation of the NPs-HS mixed solution at 10,000 rpm for 20 min. The
HS-bound PLGA NPs in the pellet were denoted as % of HS@NPs. For example, the
10% HS bound PLGA NPs were recognized as 10HS@NPs. To examine the HS protein
adsorption on PLGA NPs, the HS@NPs samples were either resuspended in PBS for a
DLS analysis or lyophilized to perform a FTIR spectroscopy.
Human Serum Protein Adsorption of PLGA NPs
The HS protein adsorption on PLGA NPs was determined by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis as described [87].
Briefly, the adsorption capacity of HS proteins was studied based on 3 protocols: 1) equal
amount (300 μg) of PLGA NPs were incubated with 600 μL various concentrations (150%) of HS for a fixed incubation period (3 h); 2) equal amount (300 μg) of PLGA NPs
were incubated with 600 μL of fixed concentration (10%) of HS for various incubation
periods (0.5, 1, 2, 3 and 24 h); and 3) various amount (10-300 μg) of PLGA NPs were
incubated with 600 μL of fixed concentration (10%) of HS for a fixed incubation period
(3 h). After completion of the incubation, the HS@NPs were obtained by centrifugation
at 10,000 rpm for 20 min. The supernatant which contained unbound HS proteins were
removed. The pellet which contained HS-bound NPs were resuspend in 600 μL PBS and
denatured by heating to 95 qC for 5 min. The HS@NPs samples were separated by size in
a 10% SDS-PAGE analysis using the constant voltage of 150 V for 75 min. The SDSPAGE gel was processed for a Bio-Safe™ Coomassie Stain (BioRad; Hercules, CA), and
scanned using a BioRad Gel Doc.
Hemocompatibility Assay
Red blood cells (RBCs) were collected from the de-identified human blood. The
freshly collected RBCs were resuspended in RPMI phenol red free media for a hemolysis
assay as described in our previous report [87]. Briefly, the RBC suspension (600 μL) was
incubated with 11-447 μg/mL EVG or equivalent concentrations of PLGA-EVG,
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30HS@PLGA-EVG, and PLGA-Blank, 30HS@PLGA-blank in Eppendorf tubes for 3
hours at 37 °C. After incubation, the experimental tubes were centrifuged at 1000 rpm for
10 min. The experimental tubes were used for visual inspection and and the supernatant
was transferred to a 96-well plate to measure the release of hemoglobin using a plate
reader (Cytation 5 imaging, BioTek, Winooski, VT) at 570 nm. Ten microliters of RBCs
from the pellet were imaged on a glass slide using an AMF4300 EVOS® FL Imaging
System (Life Technologies). RBCs dissolved in MilliQ water was used as positive
control #1 (100% hemolysis). SDS was used as positive control #2 (hemo-toxicity), and
PBS was used as negative control (0% hemolysis) in this experiment.
Biocompatibility Assay with Macrophages and Microglia
Cellular toxicity assay was performed on both MDM and MMG in the presence of
EVG native drug, PLGA-EVG NPs, and HS30@PLGA-EVG using an XTT cell viability
kit (Cell Signaling; Danvers, MA). In this study, MDM and MMG were seeded into 96well plates (2×104 cells per well) and grown in a humidified cell culture incubator at 37
°C in a with 5% CO2. Cells were treated with 0-44.5 μg/mL of EVG or equivalent
concentrations of PLGA-EVG, and HS30@PLGA-EVG for 24 hours. The cells were
washed twice with PBS and replaced with 100 μL fresh media. Subsequently, 50 μL of
XTT detection solution, which contains electron coupling solution, was added to each
well of the 96-well plate. MDM and MMG were incubated with XTT detection solution
for 3 hours and absorbance was measured using a plate reader at 450 nm. The percentage
of viable cells from treatment groups was calculated by comparing the absorbance with
the untreated cells. Data presented are from five replicates. The morphology of MDM
and MMG after incubated with different conditions were observed using EVOS® FL
Imaging System.
Sub-Cellular Localization in Macrophages and Microglia
In this study, C6, which serves as green fluorescent marker were loaded on PLGA
NPs (PLGA-C6 NPs) to visualize the sub-cellular localization of the NPs. Both MDM
and MMG were seeded on 4-well cell culture chamber glass slides (CellTreat; Pepperell,
MA). Cells were treated with 2.5 μg/mL of PLGA-C6 NPs for 2 hours. Subsequently,
cells were incubated with 30 nM MitoTrackerTM Deep Red, 50 nM Texas RedTM
Conjugate, 50 nM CellLightTM Late Endosomes-RFP, 75 nM LysoTrackerR Red DND99 as markers for mitochondria, early endosome, late endosome, and lysosome,
respectively, for 30 minutes. After the incubation, cells were fixed using 4%
paraformaldehyde for 20 minutes and permeabilized with 0.2% TritonX-100 for 5
minutes. All the cells were stained with DAPI (Life Technologies) and mounted in
Vectashield Mounting Medium (Vector Labs, Burlingame, CA) to visualize nuclei. All
the images were taken using a laser confocal microscope (Carl Zeiss LSM 710;
Oberkochen, Germany) under 400× magnification using an oil immersion objective.
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Cellular Uptake and Internalization Mechanism in Macrophages and Microglia
MDM and MMG were seeded in 6-well plates at a density of 8×105 cells/well.
The cells were pretreated with multiple endocytosis inhibitors for 30 min at 37 °C. The
inhibitors used included nocodazole (10 μg/mL), Cyto-D (10 μg/mL), CPZ (10 μg/mL),
monensin (200 nM), genistein (200 μM), and MβCD (1mM) to suppress microtubulerelated endocytosis, macropinocytosis, clathrin-mediated endocytosis, lysosome-involved
internalization, caveolae-mediated endocytosis, and caveolae-/clathrin-mediated
endocytosis, respectively. The cells were then incubated with 2.5 μg/mL PLGA-C6 NPs
for 2 hours at 37 °C. After the treatment, cells were washed twice with PBS, trypsinized,
and collected to measure the cellular uptake. Semi-quantitative PLGA-C6 uptake in
MDM and MMG were measured using Accuri C6 Flow Cytometer (Accuri Cytometer
Inc, Ann Arbor, MI), and images were taken using a laser confocal microscope (Carl
Zeiss LSM 710) under 400× magnification using oil immersion objective as described
above.
Construction of the In Vitro BBB Model
The immortalized mouse brain endothelial cells (bEnd.3, CRL-2299) and mouse
astrocytes (C8-D1A, CRL-2541) were purchased from American Type Culture
Collection. Mouse brain endothelial cells (bEnd.3) and mouse astrocytes (C8-D1A) were
cultured in complete media (DMEM media with 10% fetal bovine serum and 1%
penicillin-streptomycin solution in T75 flasks at 37 °C in a humidified incubator with 5%
CO2 before building the in vitro BBB model. Transwell® -COL collagen-coated 0.4 μm
pore polytetrafluoroethylene membrane inserts (Sigma-Aldrich) were used to build an in
vitro BBB model as previous published protocols [88, 89]. Mouse astrocytes were seeded
on the bottom of 12-well plates at a density of 2×104 cells/well. After 24 hours of
adhesion, mouse endothelial cells were seeded onto the upper side of the Transwell®COL inserts at a density of 2×104 cells/well, and the inserts were placed in a 12-well
plate containing astrocytes. The in vitro BBB model including both endothelial cells and
astrocytes was grown for 5 days to achieve ~90% confluency for transmigration assay.
Transendothelial Electrical Resistance Measurements
The integrity of the tight junction dynamics of the BBB model was measured in
terms of transendothelial electrical resistance (TEER) using an EVOM2 Epithelial
Voltohmmeter (World Precision Instruments, Sarasota, FL) [90]. The EVOM2 meter was
calibrated with a 1000 Ohm test resistor before using. The electrodes from the EVOM2
meter were sterilized by putting in 70% ethanol for 5 min. Subsequently, the electrodes
were preconditioned with the in vitro BBB cells complete growth media for 5 min. The
TEER values were obtained by putting the shorter electrode into the insert and the longer
electrode into the bottom chamber of the Transwell® plate to create a current that passed
through the membrane. TEER values were measured regularly every 24 hours for 6 days
from the day of cell seeding. The TEER values were also measured during the
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experiment period to assess the integrity of the endothelial cell layer. TEER of the blank
insert with media alone was subtracted from the TEER final reading to obtain the TEER
value for the endothelial monolayer. The TEER value was presented as the value of
resistance (current, Ohm) multiplied by the area (cm2) of the endothelial monolayer
(OhmӦcm2). The electrodes from the EVOM2 meter were cleaned with 1% Terg-a-zyme®
solution to remove the protein or other foreign materials which coated on the electrode
after each use.
In Vitro BBB Transmigration Study of PLGA NPs
The transmigration of PLGA NPs was visualized and measured using
fluorescence dye C6 in a confluent in vitro BBB model. PLGA-C6 NPs at concentrations
of 2.5, 5, and 10 μg/mL were added to the upper inserts and incubated at 37 °C for 24
hours. After incubation, astrocytes in the bottom chamber were washed twice with PBS.
The media of the bottom chamber was measured using a fluorescence plate reader
(SpectraMAX M2e, Molecular Devices; San Jose, CA) with excitation at 488 nm and
emission between 400 and 650 nm. The transmigration of PLGA-C6 NPs was presented
in terms of fluorescence intensity. C6 concentration in the media was also calculated
using a C6 calibration curve with the matrix of media. The images of recipient astrocytes
were taken via EVOS® FL Imaging System.
Penetration of PLGA-EVG NPs in the In Vitro BBB Model
The in vitro BBB model was used to assess the penetration of the PLGA-EVG
NPs. We performed a 24-hour EVG native drug or PLGA-EVG NPs treatment on the
BBB cells. EVG native drug/PLGA-EVG NPs at concentrations of 2.5, 5, and 10 μg/mL
were added to the upper inserts and incubated at 37 °C for 24 hours. A sample of 50 μL
of recipient cell media was collected at 1, 3, 6, 9, and 24-hour time points, and an equal
volume of fresh media was added. At the end of the experiment, the cells from the bottom
chambers were collected in RIPA buffer and collected. The amount of EVG flux to the
bottom chambers from both media and cell lysate was measured using LC-MS/MS
method.
Mechanistic Contribution of P-gp in Opposing the Penetration of EVG Across the
In Vitro BBB Model
The mechanistic contribution of P-gp in interfering with the penetration of EVG
was assessed in the presence and absence of the P-gp inhibitor elacridar. The in vitro
BBB layer were pre-incubated with or without elacridar (500 nM) for 30 min before a
penetration study. After pre-incubation, 5 μg/mL of EVG native drug or PLGA EVG NPs
were added to the upper inserts and incubated at 37 °C for 24 hours. A sample of 100 μL
of media from the bottom chamber was collected at 1, 3, 6, 9, and 24-hour time point, and
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an equal volume of fresh media was added. The amount of EVG flux to the bottom
chambers was measured using LC-MS/MS.
EVG Levels in the In Vivo Mouse Model
Male NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice were purchased from Jackson
Laboratory (Bar Harbor, ME) and allowed to acclimate in the animal facility for at least 7
days. A total of 16 mice were divided into two groups: one group of 8 mice was injected
intraperitoneally (i.p.) with 20 mg/kg EVG native drug in 0.1-0.2 mL of PBS. Another
group of 8 mice was injected i.p. with 20 mg/kg of PLGA-EVG NP in 0.1-0.2 mL of
PBS. Mouse blood was collected at 3, 9, 24, 48, 72, and 96 hour timepoints in EDTAcontaining blood collection tubes following a serial tail sampling procedure [91]. Briefly,
for each mouse, mouse was placed in a mouse restrainer and mouse tail was pre-warmed
by putting the tail at 37 °C of water for 2 min. A 25 G needle was used to stick the tail
and ~ 20-50 μL blood was quickly collected using a pipette. For each mouse, the first
time point was collected at the distal end of the tail, and each subsequent time point was
collected a few millimeters up from the previous stick towards the base of the tail. After
collection, the blood was quickly diluted by equal volume of PBS. Mouse blood was
settled down at room temperature and then centrifuged at 6,000 rpm for 10 min for
plasma harvesting. After blood collection, the mice were sacrificed by exsanguination
under deep isoflurane anesthesia, followed by cervical dislocation at 96 hours. Then, the
brain tissues were harvested. Mice plasma and brain tissues were placed into tubes and
frozen at -80 °C until further analysis by LC-MS/MS. All experimental protocols
involving the use of laboratory animals were approved by the UTHSC Institutional
Animal Care and Use Committee (IACUC).
Viral Suppression of PLGA-EVG NPs in HIV-1-Infected Macrophages and
Microglia after Crossing the In Vitro BBB Model
To determine the efficacy of the viral suppression of PLGA-EVG NPs, we used
HIV-1-infected primary MDM and MMG to create a modified in vitro BBB model in a
Transwell® plate. The confluent brain endothelial monolayer was obtained as described
in the previous section. The upper insert of the in vitro BBB model containing confluent
brain endothelial cells was transferred to the 12-well plate containing HIV-1-infected
MDM or MMG, and co-cultured with the infected cells. In this modified in vitro BBB
model, HIV-1-infected MDM/MMG were cultured on the bottom of the 12-well plate.
Endothelial monolayers in the upper inserts were exposed to control, blank PLGA NPs,
EVG native drug (5 μg/mL), and PLGA-EVG NPs (5 μg/mL) for 7 days. HIV-1 viral
loads from the culture media of the bottom chamber were measured every day using a
p24 ELISA kit. The upper inserts were replaced with fresh BBB cells after 3 days to keep
BBB monolayer confluent. A mean TEER value of 100 to 120 Ohmڄcm2 was obtained
every day and was consistent with the modified BBB model during the time of the
experiment. All the HIV-1- related experiments were performed in the BSL-3 laboratory
in the Regional Biocontainment Laboratory of UTHSC.
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Viral Suppression of PLGA-EVG NPs in HIV-1 Encephalitic (HIVE) Mice
Four-week-old male NSG mice were purchased from The Jackson Laboratory
(Bar Harbor, ME). All experimental protocols involving the use of laboratory animals
were approved by the IACUC of the University of Nebraska Medical Center and the
NIH. To create the HIV-1-infected mouse model, NSG mice were administered i.p. with
anesthesia ketamine/xylazine (100 mg/kg ketamine and 16 mg/kg xylazine), NSG mice
were injected bilaterally into the basal ganglia with 5x105 cell suspension in 5μL
containing HIV-1 ADA-infected MDM (total n = 6). Fourteen days after the MDM
injection, the animals were injected i.p. with vehicle control (PLGA-Blank NPs), EVG
native drug, or PLGA-EVG NPs in 0.1-0.2 mL of 5% dextrose divided in three times on
the first day to reach the dose of 200mg/kg (n=2 in each group). Mice were sacrificed on
day 5 after the drug injection. Brain samples were collected and used for RNA
extractions, and CNS HIV-1 p24 levels were assessed by measuring HIV-1 gag RNA
levels using RT-PCR. GAPDH was used as a housekeeping gene in this RT-PCR
analysis.
Statistical Analysis
All graphs and statistical analyses were performed using GraphPad Prism 5
(GraphPad Software; La Jolla, CA). The statistical significance between two groups was
determined by student’s t-test analysis. The statistical significance among treatment
groups with individual variable was determined by one-way ANOVA Tukey HSD posthoc test. The statistical significance among treatments groups with two variables were
determined by using two-way ANOVA with a Bonferroni post-hoc test. A p-value ≤ 0.05
was considered to be significant.
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CHAPTER 4.

RESULTS AND DISCUSSION1

Novel EVG Nanoformulation Approach to Suppress the Viral Load in HIV-1Infected Macrophages
Monocyte/macrophage lineage cells express the CD4 receptor and chemokine
coreceptors for entry of HIV-1 [1]. Thus, they perform an important role in initial HIV-1
infection. Monocytes and macrophages are resistant to HIV-induced apoptosis and are a
crucial reservoir for the virus [92, 93]. ARVs has notably improved the life of HIV-1
infected patients. However, it is difficult to maintain therapeutic levels of ARVs in
monocytes and macrophages because of drug efflux transporters and drug metabolic
enzyme cytochrome, such as MRP1 and CYP3A4, respectively, are expressed in these
cells [94-96]. INSTIs showed a higher antiviral activity in PBMCs and macrophages than
lymphocytic T cells, while PIs show a 2- to 10-fold lower efficacy in monocytes than in
T-lymphocytes [97, 98]. Thus, a new strategy to improve the bioavailability and efficacy
of the ARVs in monocytes and macrophages may be achieved by INSTIs.
Most ARVs are the substrates of efflux transporters and drug metabolic enzymes,
requiring combination therapy and high doses for treatment [25]. HIV can also
potentially develop resistance to treatment with these drugs [99, 100]. EVG, one of the
most prescribed and the newest class of ARVs, is also a substrate of CYP3A4 [101].
Thus, in many regimens EVG is formulated with cobicistat, a CYP3A4 inhibitor, as a
pharmacological enhancer [86, 102]. Therefore, it is desirable to develop a NP-based
formulation for EVG that is likely to bypasses drug transporters and metabolic enzyme in
the liver as well as in HIV-1-infected monocytic cells. The main objective of this chapter
is to develop an EVG nanoformulation that shows increased efficacy in monocytic cells.
Physiochemical Characterization of PLGA-EVG NPs
To ensure that there is no significant difference in particle size of PLGA NPs
when introduced to in vitro conditions, we measured the particle size both in water and
cell culture media. Before drug loading, blank PLGA NPs were measured for particle size
by DLS, and demonstrated a size of 80+4.43 nm and 89+4.13 nm in water and cell
culture media, respectively. To further determine if drug loading to these particles causes
-------------------1
Portions of chapter from previously published article; final submission modified with
permission. Gong, Y., et al. (2017). Novel elvitegravir nanoformulation approach to
suppress the viral load in HIV-infected macrophages. Biochemistry and Biophysics
Reports, 2017. 12: p. 214-219. DOI: https://doi.org/10.1016/j.bbrep.2017.10.005 [81].
Portions of chapter reprinted from final submission with open access permission. Gong,
Y., et al. (2020) Novel elvitegravir nanoformulation for drug delivery across the bloodbrain barrier to achieve HIV-1 suppression in the CNS macrophages. Sci Rep 2020. 10,
3835. DOI: https://doi.org/10.1038/s41598-020-60684-1 [82].
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any difference in size, we conducted DLS particle size measurement of the EVG loaded
PLGA NPs. Particle size distribution histograms confirm that there is a slight increase in
the size of drug loaded particles over blank NPs, with EVG loaded PLGA NPs size of
105+1.79 nm in water and 109+4.10 nm in cell culture media (Figure 4-1A).
The slight increase in size is considered low enough for active targeting to highly
replicating HIV-1-infected cells. The zeta potential of fabricated NPs was measured using
DLS (Figure 4-1B). DLS measurements confirms that the NP has a low zeta potential of
-6.74 mV. PLGA-EVG NPs under TEM (Figure 4-1C) suggesting that PLGA-EVG NPs
have a spherical morphology and are 40-50 nm particle size. TEM measurement provided
the particle size of PLGA NPs in a dried form while DLS gave the particle size in
suspension which provided a hydrodynamic diameter that included NPs and any
molecule attached or adsorbed on the surface. Thus, the particle size obtained from TEM
measurement exhibited a smaller size compared with the size obtained from DLS
measurement. The obtained particle size range and low positive zeta potential of PLGAEVG NPs are recommended and suitable for effective drug delivery purposes [103]. The
FTIR analysis of EVG, PLGA-EVG, and blank PLGA NPs is shown in Figure 4-1D. A
broad peak between 3600-3050 cm-1 was found in PLGA-EVG and blank PLGA NPs due
to the presence of hydroxyl groups of the PLGA/F68 polymer [104, 105]. The
characteristic peak of EVG was observed in the PLGA-EVG spectrum within specified
range. The FTIR spectral analysis indicated that EVG was encapsulated in NPs. The in
vitro release of PLGA-EVG NPs in cell culture media is shown in Figure 4-1E. The
release of EVG from PLGA NPs was followed by a zero-order release profile with r2 of
0.98 in 24 h. Only ~15% of cumulative EVG release was observed at 24 h, which
suggested the potential controlled release profile of PLGA-EVG NPs. The drug release
from PLGA NPs may relate to the loading ratio of drug with the PLGA copolymer, NP
protected layer stability, and/or physicochemical properties of EVG.
PLGA is an FDA-approved biodegradable polymer with minimal systemic
toxicity used for drug delivery [106]. PLGA has been extensively used in the formulation
of many anticancer drugs [83, 107-110]. Recently, PLGA has also been used to formulate
EVG and tenofovir alafenamide using emulsion solvent evaporation method for longacting prevention of HIV-1 vaginal transmission [70]. The PLGA NP formation in our
study is an oil-in-water (o/w) emulsification, which is an ideal method for waterinsoluble drugs [111]. PLGA is the main polymer core to hold EVG molecules, PVA is
used to stabilize the emulsion, poloxamer 188 (Pluronic polymer F68) is used as a
stabilizer and to reverse drug resistance, and PLL is used to provide slight positive
charge, which helps internalization into the target cells [106, 112, 113]. According to our
results, PLGA-based EVG formulation is within the size range of 50 nm, so it is easily
diffused through cell membrane to deliver the drugs.
Cellular Uptake of PLGA NPs
The cellular uptake study was performed using the fluorescence dye C6. To
ensure that the C6 loaded PLGA NPs were of similar size to the parent moiety, we
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Figure 4-1. Physiochemical characterization of PLGA-EVG NPs.
(A) DLS-based particle size distribution. (B) Zeta potential of PLGA-EVG NPs. (C)
Morphology of PLGA-EVG NPs as viewed under TEM by using AMT camera at a direct
magnification of 100,000x. Bar equals to 100 nm in the TEM image. (D) FT-IR spectral
confirmation for drug encapsulation. (E) In vitro release profile of PLGA-EVG NPs.
Mean r SEM values were graphed from 3 independent experiments. * indicates p <
0.05.
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measured the particle size by DLS prior to this study. PLGA-C6 NPs were 85+2.83 nm
and 93+2.90 nm in water and medium, respectively. The cellular uptake of PLGA NPs in
monocytes was presented in terms of mean fluorescence intensity.
A time-dependent increase in fluorescence intensity was observed (Figure
4-2A-B), with the highest fluorescence after 4 hours of exposure. Similarly, an increase
in fluorescence intensity was observed with increasing concentrations of C6 (Figure
4-2C-D). The highest fluorescence was observed in the cells treated with 10 μg/mL C6.
Overall, the results showed that cellular uptake of PLGA NPs followed time- and
concentration-dependent profiles.
Intracellular EVG Concentration and Viral Suppression Efficacy of PLGA-EVG
NPs in Macrophages
To evaluate the intracellular concentration of EVG, we performed LCMS-MS
using RTV as an internal control. EVG and RTV are eluted separately at approximately
3.27 and 2.72 min, respectively (Figure. 4-3A). The standard curve was achieved over
the range of 1-500 ng/mL using linear regression (r2 = 0.99) with a weighting factor of
1/x2. We performed a short-term EVG/PLGA-EVG treatment on U1 cells. The time
profiles of EVG and PLGA-EVG as the percentage of initial EVG concentration up to 72
hours are shown in Figure 4-3B. The results showed an overall increased EVG
concentration in PLGA-EVG NP treatment compared to EVG alone. When compared
each measured time point, PLGA-EVG NP showed a significance increase in EVG
concentration compared with EVG alone. Furthermore, we calculated AUC(0-t) for EVG
from both PLGA-EVG and EVG alone. AUC(0-t) of PLGA-EVG showed a significant
(~2-fold) increase compared to EVG alone (Figure 4-3C, *p<0.5). These results
demonstrate that the PLGA-EVG NPs improve the intracellular delivery and drug
retention in U1 cells
To determine the efficacy of the viral suppression of PLGA-EVG NPs, HIV-1infected primary macrophages were exposed to vehicle control, blank PLGA NPs, EVG,
or PLGA-EVG NPs for 9 days. HIV-1 p24 protein levels were measured every 24 hours,
and the results are shown in Figure 4-4A. PLGA-Blank NPs showed no effect on viral
replication. When compared the overall effect with control cells, both EVG and PLGA
EVG NPs showed a decreased viral load. When compared the treatment efficacy on each
measurement days, cells treated with PLGA EVG NPs showed a decreased viral load
compared with control cells from day 2 to day 5, and a better antiviral efficacy on day 4
and day 5 compared with EVG treated cells.
Since HIV-1 replicates within the cells, intracellular drug concentrations are
important to determine the efficacy of ARVs [94]. The intracellular concentrations of
ARVs, especially PIs and INSTIs, are dependent on the drug metabolizing enzyme
CYP3A4, and on efflux transporters, such as MRP1 and P-gp [86, 96, 114, 115]. These
transporters and metabolic enzymes are highly abundant in the gut and liver, and is the
main cause for developing resistance [116]. To enhance the bioavailability of these
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Figure 4-2. Cellular uptake of nanoparticles.
(A-B) Time-dependent cellular uptake of PLGA NPs in monocytic cells. (C-D)
Concentration-dependent uptake of NPs in monocytic cells. Qualitative uptake was
confirmed by EVOS® FL Imaging System and semi-quantitative uptake was determined
by Accuri C6 Flow Cytometer. Bar equals to 200 μm in microscopic images B, D. *
indicates p<0.05 compared with PLGA-Blank, # indicates p<0.05 compared with the
previous time point/concentration.
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Figure 4-3. Intracellular EVG concentration in U1 cells.
(A) LC/MS chromatogram peaks of EVG and its corresponding internal standard (IS),
RTV as well as standard curve for EVG measurement. (B) Concentration time profile of
EVG and PLGA-EVG NPs in U1 cells. (C) Area under the curve (AUC) of EVG and
PLGA-EVG NPs. Mean ± SEM values were graphed from 3 independent experiments.
*indicates p<0.05 compared to EVG alone treatment.
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Figure 4-4. Viral suppression of PLGA-EVG NPs.
(A) Time course of HIV replication upon drug exposure in HIV-1-infected MDM. Mean
± SEM values were graphed from 3 independent experiments. (B) A hypothetical
mechanism that may explain the higher EVG concentration in PLGA-EVG NPs than
EVG alone. *indicate p<0.05 compared to control; #indicate p<0.05 compared to EVG
alone treatment. Mean ± SEM values were graphed from 3 independent experiments.
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ARVs, potent inhibitors of CYP3A4 such as cobi are generally used. We have recently
shown the abundance of drug transporters and CYP3A4 in monocytic cells [95, 96].
Thus, bypassing transporters and CYP3A4 is considered as an effective strategy to
improve the ARV intracellular concentrations, especially in monocytic cells. Literature
reports suggest that NPs-based drug delivery would bypass the efflux transporters such as
P-gp [117-119], as well as liver metabolism [120]. The hypothetical mechanism behind
the difference in intracellular concentrations of EVG and PLGA-EVG in macrophages is
shown in Figure 4-4B. Based on our findings, we hypothesize that higher concentration
of EVG in PLGA-EVG treatment than EVG alone results from its likely protection from
drug transporter P-gp and metabolic enzyme CYP3A4. Our hypothesis is further
strengthened from the literature data that the concentration of ARVs is relatively lower in
P-gp- and CYP3A4-expressing monocytic cells than in lymphocytic cells [2, 5-7].
Moreover, co-administration of EVG with cobicistat is relatively expensive, and is not
affordable to African and Asian countries where HIV-1 prevalence is the highest. The use
of multiple drugs are also likely to cause drug-drug interactions, leading to toxicity in
individuals who also take other drugs that are the substrates, inducers, or inhibitors of
CYP3A4 [121, 122]. Thus, developing an optimal EVG formulation without cobicistat
can minimize these drug-drug interactions. Compared to EVG alone, the PLGA-EVG
NPs can provide a high intracellular drug concentration without need for a
pharmacoenhancer, and present relatively greater viral suppression in primary
macrophages. Overall, this formulation is a step forward to develop EVG nanomedicine
that suppresses viral replication at a relatively low dose. Because of the prolonged viral
suppression time, this nanoformulation is also likely to reduce the probability for
developing drug resistance.
Stability, Protein Corona, Biocompatibility, and Cellular Internalization Pathway of
EVG Nanoformulation
In the previous section, we developed a PLGA-based nanoformulation containing
EVG. Our PLGA-EVG NPs showed improved intracellular uptake of EVG in
macrophage cell line and viral suppression in HIV-1-infected primary macrophages. As
part of the recommended initial regimen for the majority of HIV-1-infected populations
in the USA [68], researchers started formulating EVG into NPs to combat HIV-1
infection in the last three years [69, 70]. For example, EVG has been formulated into
PLA NPs with a HPG coating on the surface [69]. These PLA NPs were distributed
widely throughout the reproductive tract, and showed a prolonged intravaginal delivery
of EVG. Moreover, EVG has been used together with tenofovir alafenamide in a PLGAbased NPs coated with poloxamer 407 as a prevention strategy to against HIV-1 [70].
These EVG NPs can extend the half-life t1/2 of EVG from 10.8 hours to 3.3 days and
protect mice with 100% and 60% uninfected rate on day 4 and day 14 post-nanoparticle
injection after a HIV-1 challenge. Although these studies have demonstrated the use of
nanocarriers to deliver EVG, none of these strategies have moved to clinical research yet.
One of the reasons is the limited understanding of the fate and biosafety of NPs in the
physiological system [87]. For example, it is expected that human serum protein binding
occurs when NPs are administer to human subjects [123]. Upon introduction of NPs into
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the body, NPs dynamically interact with serum proteins and form the NP-protein
complexes [124]. Understanding the interaction of NPs with HS can predict their safety
and efficacy profiles when used in the clinic [123].
In addition, determination of hemocompatibility with red blood cells (RBCs) is
important for a formulation which is intended for systemic administration, as an
incompatible formulation may lead to a thromboembolism which can cause the death of
the patient [125]. Therefore, the aim of this chapter is to identify the interaction of HS
proteins and PLGA NPs, and the subsequent effect on hemocompatibility with RBCs and
biocompatibility with macrophages and microglia. In addition, we also identified the
internalization mechanism of the PLGA NPs in macrophages and microglia to further
understand the interaction of PLGA NPs with HIV-1 reservoirs macrophages and
microglia in the CNS.
Stability of PLGA NPs
First, a stability study was performed for the PLGA NP formulation to establish
expectations for the storage shelf life of the prepared formulation. The size of freshly
made PLGA NPs was approximately 135.7 ± 1.5 nm in PBS (Table 4-1). PLGA NPs
were stable at room temperature for at least a week. No specific change in particle size or
zeta potential of NPs was observed for 7 days when stored at room temperature. PLGA
NPs can be stored at 4 °C and -20 °C for at least 30 days with no change in particle size
or zeta potential. PLGA NPs showed a stable particle size in 1 mM HEPES buffer within
the pH range of 1-11 (Table 4-2). PLGA NPs showed a positive charge (~7 mV) at all
the recorded pH values except pH 4, 5, and 11. A higher positive charge (~20 mV) of
PLGA NPs was observed at the pH range of 4-5, and a lower charge (~ 3 mV) of PLGA
NPs was observed at pH 11
Evaluation of Human Serum Protein Binding on PLGA NPs
We showed the existence of an HS protein corona on PLGA NPs using DLS,
FTIR, and SDS-PAGE analyses. A DLS assay of PLGA NPs was investigated in PBS
and 1-50% HS. An increase in particle size to ~200 nm was observed for PLGA NPs in
1-50% HS (Figure 4-5A). The reason of the increased particle size is due to the binding
of HS protein onto PLGA, which establishes a soft corona[87]. HS proteins are loosely
bound to the PLGA NPs, leading to this increase in particle size. The increased size of
PLGA NPs is acceptable because NPs with size of 200 nm can be taken up by human
brain endothelial cells efficiently [126]. Previous study also showed that NPs with size of
200 nm also provided a compatible BBB transportation compared with NPs with size of
100 nm [127]. For polymeric NPs, the size between 60 nm to 200 nm still considered to
have a very large surface-to-volume ratio to show the optimal drug uptake. Zeta potential
of PLGA NPs was observed to be negative in 1-50% HS (Figure 4-5B). This negative
charge is expected, because HS is negatively charged in pH 7.4 PBS. The negative zeta
potential indicates that PLGA NPs are stable and safe for therapeutic applications. PLGA
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Table 4-1.

Size and zeta potential of PLGA NPs stored at room temperature, 4 °C and -20 °C.

Days
Size (nm)
Zeta potential
(mV)

Day 0
135.7
±1.5
0.11
±0.5

Day 1
134.4
±0.7
-0.53
±0.3

Room temperature
Day 2 Day 3 Day 4 Day 5
135.5 135.7 132.6 134.2
±0.5
±0.4
±0.6
±1.3
-0.18 -0.02 0.62
-0.37
±0.3
±0.2
±0.2
±0.2

Day 6
135.9
±1.4
0.00
±0.2

Day 7
134.6
±1.2
-0.18
±0.3

4 °C
Day 7 Day 30
132.1 133.1
±0.5
±0.5
-0.25 -0.22
±0.2
±0.3

-20 °C
Day 7 Day 30
131.9
132.9
±0.2
±0.3
-0.02
-0.12
±0.3
±0.3

Mean ± SEM values were calculated from three measurements. Size and zeta potential of NPs from different storage conditions were
compared with day 0, room temperature sample.

Table 4-2.

Size and zeta potential of PLGA NPs in 1mM HEPES buffer from pH 1 to pH 11.

pH range
Size (nm)
Zeta potential
(mV)

pH 1
132.2
±1.0
7.02
±0.2

pH 3
132.5
± 0.8
6.36
±0.6

pH 4
134.4
± 0.8
18.87
±1.8

pH 5
133.8
±0.9
22.27
±0.4

pH 6
132.1
±0.4
7.72
±1.3

Mean ± SEM values were calculated from three measurements.
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pH 7.4
132.0
±0.4
7.94
±0.75

pH 8
131.5
±1.2
6.90
±0.55

pH 10
126.9
±0.7
5.87
±0.34

pH 11
128.3
±1.5
3.40
±0.31

Figure 4-5. Evaluation of human serum protein binding on PLGA NPs.
(A) Particle size of PLGA NPs in 1-50% HS. (B) Zeta potential of PLGA NPs in 1-50%
HS. (C) FTIR spectra of HS, PLGA NPs and HS@NPs. (D-E) SDS-PAGE of adsorbed
HS proteins on PLGA NPs. Data represents HS proteins binding to PLGA NPs dependent
on the (D) concentration of HS, (E) incubation time, and (F) concentration of PLGA
NPs. Mean ± SEM values are from 3 independent experiments.
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NPs did not precipitate in the presence of HS. To confirm the HS binding on PLGA NPs,
we performed a FTIR analysis of PLGA NPs, HS, and HS-bound NPs. The FTIR data
was presented from 600 to 1800 cm-1 to observe the HS protein peaks. Peaks at 1661 cm-1
and 1541 cm-1 were found in HS and HS@NPs due to the amide bond stretch of the HS
proteins. The peak extent of the HS proteins in HS@NPs showed a concentrationdependent increase with increasing percentage of HS (Figure 4-5C). Moreover, we
further confirmed the PLGA NPs-protein interaction using SDS-PAGE analysis, in
which, it can be observed the HS proteins binding on HS@NPs. The identified major
proteins that bind on NPs are: transferrin, human serum albumin (HSA), fibrinogen beta,
fibrinogen gamma, apolipoprotein E (Apo E), and apolipoprotein A1 (Apo A1), based on
molecular weight [128]. The adsorbed HS proteins Apo E and Apo E have been shown to
improve brain delivery of PLGA NPs [129]. We found that HS proteins were adsorbed to
the surface of PLGA NPs when the concentration of HS increased (Figure 4-5D). With
an increased incubation time, an increased protein binding on the PLGA NPs was also
observed (Figure 4-5E). HS protein binding also showed an increased pattern when the
amount of PLGA NPs was increased up to 180 μg while after which HS protein binding
decreased (Figure 4-5F). This indicates the saturation of binding with NPs due to the
limited HS amount and incubation time.
Hemocompatibility and Biocompatibility of PLGA-EVG NPs
Hemocompatibility tests evaluate the effects on RBCs when a foreign compound
is introduced to the blood. Both visual inspection (Figure 4-6A) and spectrophotometric
measurement of hemoglobin release (Figure 4-6B) suggested that PLGA NPs do not
cause hemolysis even at the highest concentration (200 μM) that was used in the assay. A
dose dependent hemolysis was observed in RBCs treated with EVG native drug. At the
highest tested concentration (200 μM), EVG native drug caused ~30% hemolysis while
PLGA-EVG NPs did not cause hemolysis. Similarly, HS30@EVG NPs also caused low
hemolysis (~4%) compared to EVG native drug (~30%). Moreover, EVG native drug
caused morphology change in RBCs, while PLGA-EVG NPs and HS30@EVG NPs
caused no change in RBC morphology (Figure 4-6C). The hemocompatibility of PLGA
NPs could be because of the biocompatibility of the polymer and the HS adsorption on
the PLGA NPs.
It is important to carefully control the biocompatibility and cytotoxicity of a
biomaterial for the potential use in the clinic [130]. Thus, we evaluated the toxicity
profile of PLGA-EVG NPs with MDM and MMG. Over the range of 0-20 μM EVG,
PLGA-EVG or 30HS@EVG NPs, ~100% cell viability was observed with all these
groups when compared to control cells (Figure 4-7A-B). No change in cell morphology
was observed even after treating with the highest concentration (20 μM) of EVG native
drug, PLGA-EVG NPs, or HS30@PLGA-EVG (Figure 4-7C).
In conclusion, it is expected that HS protein binding occurs upon incubation with
different percentage of HS due to the hydrophilic polymer PEG and hydrophilic groups
of poloxamer 188. The dynamic corona formed on PLGA NPs did not significantly alter
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Figure 4-6. Hemocompatibility of PLGA NPs.
(A) Visual inspection of the tubes containing RBCs after exposure to 5-200 μM EVG,
PLGA-EVG NPs, HS30@EVG NPs, Blank NPs, and HS30@Blank NPs. (B) Hemolysis
of RBCs upon incubation with 5-200 μM EVG, PLGA-EVG NPs, HS30@EVG NPs,
Blank NPs, and HS30@Blank NPs. (C) Microscopic images of RBCs treated with 447
μg/mL EVG, PLGA-EVG NPs, HS30@EVG NPs, Blank NPs, and HS30@Blank NPs.
1X PBS was used as negative control, water was used as positive control #1, and sodium
dodecyl sulfate (SDS) was used as positive control #2. % of hemolysis was calculated
based on the positive control #1 (water). Data represents triplicates.
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Figure 4-7. Toxicity evaluation of PLGA-EVG NPs in MDM and MMG.
(A-B) Cell viability of MDM and MMG with the treatment of 0-44.5 μg/mL EVG, PLGA-EVG NPs, and 30% HS bound-PLGA-EVG
NPs complexes (HS30@PLGA-EVG), measured by XTT assay. (C) Microscopic images of MDM and MMG with the treatment of 0
and 44.5 μg/mL EVG, PLGA-EVG NPs, and HS30@PLGA-EVG. 5% acetonitrile was used as a positive control. Mean ± SEM values
are from 5 replicates.
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the particle size of PLGA NPs, nor their hemocompatibility, or biocompatibility to
macrophages and microglia, while it did alter zeta potential
Internalization Mechanism of PLGA NPs in Macrophages and Microglia
In the previous section, we showed a time- and concentration-dependent uptakes
of PLGA NPs in monocytes. To further study the endocytosis pathways of these PLGA
NPs in macrophage and microglia, various endocytosis inhibitors were utilized. The
inhibitors include nocodazole, Cyto-D, CPZ, monensin, genistein, and MβCD, which
suppress microtubule-related internalization, macropinocytosis, clathrin-mediated
endocytosis, lysosome-involved internalization, caveolae-mediated pathways, and
caveolae-/clathrin-mediated endocytosis, respectively [131, 132]. To detect by flow
cytometry, a fluorescence probe, C6 (green) was encapsulated in PLGA NPs. The
inhibition effect of all the endocytosis inhibitors on the internalization of PLGA-C6 NPs
in MDM are minor, indicating that the internalization of PLGA NPs in MDM may relate
to a combination of endocytosis pathways (Figure 4-8A-B). In MMG cells, the cellular
uptake of PLGA-C6 NPs was diminished by the compounds with the inhibition strength
in the order of MβCD > genistein > CPZ. Among these inhibitors, MβCD inhibited up to
55% uptake of PLGA-C6 NPs, which strongly indicates that the main internalization of
PLGA NPs in MMG occurred through caveolae-/clathrin-mediated endocytosis (Figure
4-8C). We further examined the sub-cellular fate of PLGA NPs using a confocal
microscopic analysis (Figure 4-8D). PLGA NPs were efficiently internalized in both
MDM and MMG after 3 h exposure. A co-localization of PLGA-C6 and early endosome
markers were observed in both MDM and MMG cells, but less co-localization was
observed in the presence of late-endosomal marker, and no co-localization was observed
in the presence of the lysosomal or mitochondria marker. This suggests that PLGA NPs
can escape from endo-lysosomal compartments and deliver the therapeutics to the cells
efficiently.
Understanding the mechanism of internalization of NPs by the targeted cells can
increase our knowledge of how these particles are taken up and are transported within the
cells, and to what extent they are secreted [133]. In general, most of the NPs are taken up
into cells via endocytosis into endosomes and subsequently trafficked into lysosomal
compartments [134]. Literature reports have suggested that polymeric NPs are taken up
by mouse primary microglia mainly by clathrin-mediated endocytosis [135-137].
Similarly, we observed that the caveolae-/clathrin-mediated endocytosis serves as the
major pathways for human MMG to uptake PLGA NPs. In contrast to the microglia,
however, our data showed that a combination of different endocytosis pathways are
involved in the uptake of PLGA NPs into the macrophages, which is also consistent with
previous studies [138-140]. Although initially present in early endosomes, PLGA NPs
can still bypass the endo-lysosomal compartments in both MDM and MMG with less and
no co-localization found in the presence of late endosomal and lysosomal markers,
respectively. Our design allows the PLGA NPs to escape the endo-lysosomal
degradation/secretion, which helps the therapeutic to work effectively inside the
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Figure 4-8. Internalization mechanism of the PLGA-C6 NPs in MDM and MMG.
(A) Cellular uptake of PLGA-C6 NPs in the presence of various endocytosis inhibitors.
(B-C) Relative cellular uptake percentage calculated from the mean fluorescence
intensity measured by flow cytometry in MDM and MMG. Mean ± SEM are from 3
measurements. *p<0.05. (D) Co-localization evaluation of PLGA-C6 NPs (green) in
presence of markers (red) for early endosome, late endosome, lysosome, and
mitochondria. DAPI was used to stain nuclei (blue). White arrow indicates the colocalization of PLGA-C6 NPs with early- and late- endosome markers in the cells. Cells
were visualized under 400× magnification (Bar = 5 μm).
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cells [134]. To the best of our knowledge, this is the first report studying the mechanistic
internalization of NPs by human microglia.
EVG Nanoformulation for Drug Delivery Across the BBB to Achieve HIV-1
Suppression in the CNS
As described before, the introduction of antiretroviral therapy (ART) has made
significant advances in managing HIV-1/AIDS effectively [1]. However, the prevalence
of HIV-1-associated neurocognitive disorders (HAND) is still a major concern, especially
in the aging population [2]. The key cells that support productive HIV-1 infection and
replication in the brain are macrophages and microglia [8, 9]. Therefore, maintaining a
therapeutic concentration of ARVs in HIV-1-infected macrophages and microglia is
important for an effective HIV-1 treatment in the brain. Further, the expression of the
efflux transporters P-gp, and the drug metabolic enzyme, CYP3A4 in macrophages and
microglia makes it more difficult to maintain the therapeutic levels of ARVs in these cells
using conventional regimens [77-79].
NP-based drug delivery systems provide a relatively safe profile, protects ARVs
from efflux transporters as well as from enzymatic and hydrolytic degradations, and can
be used for a sustained-release of therapeutics [40]. NPs that have been studied for brain
delivery mainly include polymeric NPs such as poly(glycolic acid) (PGA), PLA, PLGA,
and PBCA NPs [41, 42], and metal-based NPs such as gold, silver, and zinc oxide NPs
[42]. Since polymeric NPs are not only easy to be prepared and stored but also highly
biocompatible and biodegradable in nature, polymeric NPs have been extensively studied
for delivery of therapeutics for cancer [43-46] and HIV-1 [47-50]. However, the use of
polymeric NPs to deliver ARVs to the brain for the treatment of HAND is still
underdeveloped.
To utilize PLGA NPs as a potential tool for drug delivery to the brain, in this
chapter, we performed the transmigration study of PLGA NPs in an in vitro BBB model
and in vivo mouse models, and subsequently assessed the efficacy of PLGA-EVG NPs on
viral suppression of HIV-1-infected primary macrophages and microglia after crossing
the BBB. Overall, PLGA NPs provided a promising method for delivery of EVG across
the BBB and have a potential for therapeutic interventions in reducing HAND.
In Vitro BBB Model and Transendothelial Electrical Resistance Assessments
The in vitro BBB model used in this study was co-cultured endothelial cells
(bEnd.3) with astrocytes (C8-D1A) in a Transwell® plate as described in Chapter 3
(Figure 4-9A). The bEnd.3 cell are a commercially available cell line and a useful BBBmimicking system for biological and pharmacological research because they expresses
the efflux transporters P-gp and breast cancer resistance protein (BCRP) [141, 142]. A
bEnd.3/C8-D1A co-culture model has shown to present significantly higher development
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Figure 4-9. In vitro BBB model.
(A) Graphical representation of the in vitro BBB model. (B) TEER measurements were
obtained by applying a transendothelial current to the membrane and then testing the
resistance (current, Ohm) multiplied by the area (cm2) of the endothelial monolayer
(Ohmڄcm2) by using an EVOM2 meter. Mean ± SEM values were graphed from 3
independent experiments.
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of tight junctions than the monoculture of bEnd.3 [89]. In our study, transendothelial
electrical resistance (TEER) values were measured for 6 days after co-culturing. We
observed that the TEER value reached a plateau on day-4 and it was stable from 4 to 6
days (Figure 4-9B). A mean TEER value of 100 to 120 Ohmڄcm2 was observed in the
confluent BBB model, which is consistent with literature reports [89]. All transmigration
experiments were conducted after membrane integrity was stable with consistent TEER
values.
Transmigration of PLGA NPs Across the In Vitro BBB
The characterization of the PLGA-C6 NPs was reported previously, which
demonstrated a time- and dose-dependent uptakes in monocytes [143]. To test the
transmigration of PLGA-C6 NPs across the in vitro BBB, three different concentrations
of PLGA-C6 NPs were exposed in the upper chamber, and the culture media in the
bottom chamber was collected after 24 hours. The penetration of PLGA-C6 NPs was
examined by quantifying the fluorescence intensity of the culture media, which was
collected from the bottom chamber. We observed a dose-dependent increase in
fluorescence intensity from media samples, which suggests a dose-dependent penetration
of PLGA-C6 NPs across the BBB (Figure 4-10A). This finding is also supported by a
quantification of C6 from the same media. C6 concentrations in the media collected from
the bottom chamber were calculated using a C6 calibration curve. The penetration of C6
across the BBB also followed a dose-dependent profile, and all the PLGA-C6 groups
showed significant increase in C6 fluorescence intensity compared with PLGA-Blank
after crossing the BBB (Figure 4-10B, *p<0.05 compared with PLGA-Blank, #p<0.05
compared with the previous concentration). These results were also validated by the
qualitative imaging of recipient astrocytes, which showed that PLGA-C6 NPs were taken
up by cells in a dose-dependent manner after crossing the BBB. The highest fluorescence
was observed in cells treated with the highest concentration of PLGA-C6 NPs (Figure 410C).
Increased Penetration of PLGA-EVG NPs in the In Vitro BBB Model and In Vivo
Mouse Model
To understand whether nanoparticle formulation can increase the transmigration
of EVG in the in vitro BBB model, we measured EVG concentrations in the bottom
chamber from both media and cell lysate samples. As expected, PLGA-EVG NPs showed
higher penetration compared to EVG-free drug. Dose-dependent penetration profiles for
both EVG-free drug and PLGA-EVG NPs were observed. A significant increase in EVG
penetration was observed for both native EVG and PLGA-EVG NPs from 2.5 μg/mL to 5
μg/mL and from 5 μg/mL to 10 μg/mL (Figure 4-11A, *p<0.05 compared with PLGABlank, #p<0.05 compared with the previous concentration). The results showed that a
maximum of 27% of PLGA-EVG NPs can cross the BBB after 24 hours. The results also
showed a significant increase in penetration of PLGA-EVG NPs compared to EVG native
drug at the dose of 5 μg/mL and 10 μg/mL. We also performed a time-dependent
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Figure 4-10. Dose dependent penetration of PLGA NPs across the BBB in vitro.
(A) Quantitative penetration of PLGA-C6 after 24 hours exposure of PLGA-C6 to the top
insert. The florescence intensities of the media from bottom chambers was determined by
SpectraMax M2e UV spectrometer. Fluorescence was studied by excitation at 488 nm
and emission between 400– 650 nm. (B) C6 concentration in the media was calculated
using a C6 calibration curve with the matrix of media. C6 concentration of 1μg/mL
represents 302101 mean florescence intensity (area under the curve). (C) Bright field,
fluorescent, and overlay images of astrocytes from bottom chambers after 24 hours
exposure of PLGA-C6 to the top insert. PLGA-C6 was taken up dose-dependently by the
astrocytes in bottom chambers after crossing the BBB. The green florescence was
visualized using an EVOS® FL Imaging System. Scale bar = 200 μm. Mean ± SEM
values were graphed from 3 measurements. * indicates p<0.05 compared with PLGABlank, # indicates p<0.05 compared with the previous concentration.
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Figure 4-11. Dose-/time-dependent penetration of EVG and PLGA-EVG NPs across
the BBB in vitro.
(A) Dose dependent penetration profile of EVG and PLGA-EVG NPs across the BBB in
vitro. (B) Time dependent penetration profile of EVG and PLGA-EVG NPs across the in
vitro BBB. Quantitative penetration of EVG was determined by LC-MS/MS. (C)TEER
of the endothelial cell layer was measured before and after treatment. * indicate p<0.05
compared with native EVG drug, # indicate p<0.05 compared with the previous
EVG/PLGA-EVG concentrations. (D) Microscopic images of the endothelial cells from
the top insert were taken before and after treatment using an EVOS® FL Imaging
System. Scale bar = 200 μm. (E) Time course penetration profile of EVG or PLGA EVG
NPs across the in vitro BBB in the presence or absence of the P-gp inhibitor elacridar. (F)
Area under the curve of EVG and PLGA-EVG penetration in presence and absence of Pgp inhibitor elacridar. Area under the curve from 0 to last time t (AUC0–t) was calculated
using the linear trapezoidal method. Mean ± SEM values were graphed from 3
independent experiments. * indicates p<0.05 compared with native EVG drug in absence
of the P-gp inhibitor.
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penetration study using 5 μg/mL of native EVG/PLGA-EVG NPs. Both native drug and
NPs showed a time-dependent penetration across the BBB model. Penetration of PLGAEVG NPs across the BBB showed a significant increase in the area under the curve
compared to EVG native drug (Figure 4-11B, *p<0.05). These results demonstrate that
PLGA-EVG NPs improve the ability of EVG to cross the BBB in the in vitro model.
Moreover, no changes were observed in TEER values (Figure 4-11C) or endothelial cell
morphology (Figure 4-11D) before and after the treatment, suggesting that PLGA-EVG
transmigration did not change the BBB monolayer integrity. Additionally, to identify the
mechanistic contribution of P-gp in interfering the penetration of EVG in the in vitro
BBB model and the capability of PLGA NPs to bypass the BBB efflux transportation.
We performed a penetration study in presence and absence of the P-gp inhibitor elacridar
for 24 hours (Figure 4-11E). The AUC (0-t) of in vitro BBB penetration for EVG
increased significantly after in the presence of the P-gp inhibitor, which indicates that the
low EVG level in the CNS is partially mediated by P-gp-mediated efflux (Figure 4-11F).
In contrast, the penetration of PLGA-EVG NPs showed no difference between the
presence or absence of the P-gp inhibitor, demonstrating the ability of NP to bypass the
efflux transporter P-gp in the in vitro BBB.
The bioavailability and brain permeability of EVG loaded on PLGA NPs were
evaluated by comparing the plasma and brain concentrations of native EVG with PLGAEVG NPs. We prepared calibration curves using blank plasma and blank brain
homogenates to quantify plasma samples and brain samples to minimize the matrix
effect, respectively. The linear calibration curve was achieved over the range of 1 - 500
ng/mL with a weighting factor of 1/y and a correlation coefficient (r2) of 0.999 for plasma
EVG (Figure 4-12A). The calibration curve for brain homogenates followed a linear
regression over the range of 1 – 125 ng/mL with a weight factor of 1/y and r2 of 0.997
(Figure 4-12B). The mean plasma concentration versus time profiles of PLGA-EVG NPs
and native EVG after intraperitoneal (i.p.) injection is shown (Figure 4-12C, *p<0.5).
The calculated mean plasma Cmax of PLGA-EVG NPs was 186 ng/mL, which is
approximately 6-fold greater than the Cmax achieved by the native drug (27.2 ng/mL). The
AUC (0-t) of the PLGA-EVG NPs was 1911 ng*h/mL, which is significantly higher than
the native drug. The higher Cmax and AUC (0-t) indicate that the nanoformulation increases
the bioavailability of EVG compared to the same dose of the free drug in mouse plasma.
Mouse brain concentrations were also measured after sacrificing the mouse at 96 h to
analyze the permeability of EVG across the BBB. Brain EVG concentration was found to
be ~3-fold higher in PLGA-EVG NPs compared with the native drug (Figure 4-12D,
*p<0.5). Overall, the data showed an improved delivery of EVG to the brain using the
PLGA NPs. Mice were healthy after injecting EVG native drug/PLGA-EVG NPs. No
adverse events, weight loss, or animal dead was observed during the study.
NPs have been demonstrated to be a promising strategy to deliver drugs at the site
of action, bypass transporters and drug metabolic enzymes, and cross the BBB [47, 49].
Thus, we hypothesize that, EVG in PLGA NPs can bypass transporters on the BBB to
produce higher drug transmigration and can also bypass those same transporters and drug
metabolic enzymes in macrophages and microglia after crossing the BBB, showing
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Figure 4-12. Plasma and brain concentrations of EVG and PLGA-EVG NPs in mice.
(A) LC-MS/MS calibration curve for EVG in plasma samples from MultiQuant Software.
(B) LC-MS/MS calibration curve for EVG in brain samples from MultiQuant Software.
(C) Plasma concentrations of EVG were measured after i.p. administration of 20 mg/kg
dose of native EVG (n = 8) or PLGA-EVG (n = 8) to mice by LC-MS/MS. Aera under
the curve (AUC) and maximum concentration (Cmax) was analyzed using noncompartmental analysis by PK solver. (D) Brain concentrations of EVG were measured
after sacrificing mice at 96-hr time point. Mean ± SEM values were graphed from eight
mice measurements for each group. *indicates p < 0.05 compared to EVG native drug.
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improved viral suppression in those cells. In order to have an efficient brain delivery, we
used poloxamer 188 as the surfactant in our PLGA NP formulation. Poloxamer 188 has
been used as an effective surfactant for brain delivery in cancer treatment [80, 145].
Literature reports have shown that poloxamer 188 coating can help PLGA NPs become
an efficient brain delivery method [80]. They demonstrated that poloxamer 188-coated
PLGA NPs have a high anti-tumor effect against an intracranial 101/8 glioblastoma in
rats, compared with the non-coated NPs. In another study, poloxamer 188-coated PLGA
NPs demonstrated the greatest cellular uptake in brain tissues when compared with NPs
coated with other commonly used surfactants such as polysorbate 80 and poloxamer 407
[145]. Similarly, in our study, the poloxamer 188-coated PLGA-EVG NPs demonstrated
an effective brain delivery profile in our study. The poloxamer 188-coated PLGA-EVG
NPs showed more than 50% higher penetration of the in vitro BBB model compared with
the native drug. Most importantly, this PLGA-EVG NPs also increase the EVG brain
penetration by 3-fold in the in vivo mouse model, compared with the native EVG.
Improved Viral Suppression in HIV-1-Infected Macrophages and Microglia after
Crossing the In Vitro BBB
Since macrophages can be infected productively by HIV-1 in the CNS [8], we
examined the viral suppression efficacy of PLGA-EVG NPs in HIV-1-infected
macrophages. We examined PLGA-EVG NPs and native EVG for their effects on viral
replication on HIV-1-infected MDM in a modified in vitro BBB model following a onemonth treatment paradigm as described in the treatment scheme (Figure 4-13A). HIV-1infected MDM were cultured on the bottom chamber, which was not exposed to EVG
directly. Blank PLGA NPs, EVG, and PLGA-EVG NPs were added on the upper
chamber, which contains the BBB monolayer. TEER values of the BBB model were
measured for all the groups daily. Both EVG and PLGA-EVG NPs did not compromise
the physiological integrity of the in vitro BBB model (Figure 4-13B). HIV-1 p24 protein
levels were measured from the bottom chamber daily. Thus, any effects on viral
suppression in the recipient MDM are the result of successful transmigration of the in
vitro BBB by EVG native drug or PLGA-EVG NPs. Our results showed that PLGABlank NPs had no effect on viral replication. Both native EVG and PLGA-EVG NPs
suppressed the viral replication to 70-100 % of control, and an increased antiviral
efficacy of PLGA-EVG NPs compared with EVG native drug on all the measured days
(Figure 4-13C). We calculated the p24 area under the curve to compare the viral
suppression efficacy of native EVG and PLGA-EVG NPs from day-1 to day-7 (Figure 413D, *p<0.5). The results showed that the HIV-1-infected MDM, when exposed to
PLGA-EVG NPs have a significantly lower viral load, indicating that PLGA-EVG NPs
have better efficacy on viral suppression in HIV-1-infected MDM after crossing the in
vitro BBB than EVG alone.
Other than macrophages, microglia also serve as a sanctuary site for HIV-1 in the
CNS, which cannot be suppressed efficiently [10]. A one-month treatment paradigm for
collecting HIV-1-infected MMG and performing EVG/PLGA-EVG viral suppression
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Figure 4-13. Viral suppression of EVG and PLGA-EVG in HIV-1-infected MDM after crossing an in vitro BBB model.
(A) Treatment paradigm for collecting HIV-1-infected MDM and performing an EVG/PLGA-EVG viral suppression study. (B) TEER
of the endothelial monolayer was measured at indicated time points. (C) Time course of HIV-1 replication upon drug exposure in
HIV-1-infected MDM after crossing in vitro BBB model. All assays were performed on triplicate samples with MDM derived from
two different donors. To minimize inter-donor variability, p24 levels were normalized to the control MDM, which were obtained from
the same donor, and reported as a percentage of the control group. (D) Area under the curve of EVG and PLGA-EVG. Area under the
curve from 0 to last time t (AUC0–t) was calculated using the linear trapezoidal method. Mean ± SEM values were graphed from
triplicate samples with MDM derived from two different donors. *indicates p < 0.05 compared to control, #indicates p < 0.05
compared to EVG native drug.
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study was used as described in the scheme (Figure 4-14A). Although the in vitro MMG
is not representative of human primary microglia, MMG have shown to express microglia
markers and possess similar morphological structure as human primary microglia [84].
As in the MDM study, the drug was exposed to the endothelial monolayer on the top of
HIV-1-infected MMG, and HIV-1 viral load was measured from the bottom chamber,
which was not exposed to EVG directly. Also, as in the MDM study, we did not observe
monolayer integrity changes during the 7-day treatment (Figure 4-14B). PLGA-Blank
showed no effect on viral load, compared with control cells. Both EVG and PLGA-EVG
NPs showed significant HIV-1 suppression in HIV-1-infected MMG after crossing the
BBB, while EVG showed no significant HIV-1 suppression on day 2. Moreover, PLGAEVG NPs showed a better viral suppression efficacy on day 1, 4, 5, and 6, compared with
EVG native drug (Figure 4-14C). The p24 AUC showed the relative ability of viral
suppression for EVG free drug and PLGA-EVG NPs. PLGA-EVG NPs showed ~25%
more viral suppression in HIV-1-infected MMG after crossing the in vitro BBB (Figure
4-14D, *p<0.5).
Currently, magnetic nanoformulation is the most commonly studied
nanoformulation for NeuroAIDS [55]. Magnetic NPs of azidothymidine showed a 3-fold
higher transmigration in an in vitro BBB model, compared to the native drug [55]. This
magnetic nanoformulation of azidothymidine also showed a slightly lower p24 antigen
production when treating with HIV-1-infected PBMCs. The same group also developed a
magnetic layer-by-layer NPs with a ~37.95% BBB transmigration and ~33% p24
suppression effects on astrocytes in vitro [56]. Compared with those magnetic NPs, our
PLGA-EVG NPs showed a comparable percentage of transmigration and viral
suppression in vitro.
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Figure 4-14. Viral suppression of EVG and PLGA-EVG in HIV-1-infected MMG after crossing an in vitro BBB model.
(A) Treatment paradigm for collecting HIV-1-infected MMG and performing an EVG/PLGA-EVG viral suppression study. (B) TEER
of the endothelial monolayer was measured at indicated time points. (C) Time course of HIV-1 replication upon drug exposure to
HIV-1-infected MMG after crossing the in vitro BBB model. All assays were performed on triplicate samples with MMG derived
from one donor. p24 levels were normalized to the control MMG, which were obtained from the same donor, and reported as a
percentage of the control group. (D) Area under the curve of EVG and PLGA-EVG treatments. Area under the curve from 0 to last
time t (AUC0–t) was calculated using the linear trapezoidal method. Mean ± SEM values were graphed from triplicate samples with
MMG derived from one donor. *indicates p < 0.05 compared to control, #indicates p < 0.05 compared to EVG native drug.
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CHAPTER 5.

CONCLUSIONS AND FUTURE DIRECTIONS

In this study, we developed a poloxamer-PLGA based NP loaded with EVG and
showed the physicochemical characterization of this PLGA NP. Our current study
demonstrated that this PLGA NP is an efficient delivery approach for EVG. The PLGAEVG NPs demonstrated a time- and concentration-dependent uptakes in monocytes and
showed a higher intracellular internalization and superior viral suppression to EVG native
drug in HIV-1-infected macrophages. The PLGA-EVG NPs demonstrated a favorable
stability and safety profile. The PLGA-EVG NPs demonstrated significant transmigration
across an in vitro BBB, and an improved plasma drug concentration and drug brain
concentrations in an in vivo mice model relative to EVG alone. PLGA-EVG NPs showed
an improvement in viral suppression in both HIV-1-infected MDM and HIV-1-infected
MMG after crossing the in vitro BBB compared with EVG native drug. PLGA-EVG NPs
also showed a trend of decreasing viral load in the CNS in the humanized HIVE mice
model compared with EVG native drug. To the best of our knowledge, this is the first
report of using EVG nanoformulation as a potential delivery method to cross the BBB
and suppress HIV-1 in the CNS. Moreover, compared to magnetic NPs, our PLGA-EVG
NPs are easy to prepare, composed of FDA-approved non-toxic NPs, and do not require
the application of an external magnetic field. We expect that PLGA-EVG NPs have the
potential to move forward toward clinical use.
There were less than 10 studies documented using the nanoformulated ARVs
according to clinical trial database (https://clinicaltrials.gov), ARVs such as efavirenz,
lopinavir, cabotegravir and rilpivirine were involved in clinical trials that includes phase
I/II/III [146]. A clinical trial (NCT02631473) conducted by St Stephens Aids Trust and
University of Liverpool showed that a 50% dose reduction can be achieved by using for
NPs for efavirenz and lopinavir compared to native drug regimens in healthy volunteers
[146]. Additionally, a long-acting form of rilpivirine of nanosuspension made with
poloxamer 338 and PEG 1000 has been investigated for safety profile in a phase II study
(NCT02165202) [147]. In this study, one patient died, and 4 patients encountered with
severe side effects among the 91 patients. Additionally, long acting nanoforumlation was
also used with an integrase inhibitor cabotegravir and conducted a randomized clinical
trial (NCT02076178), and showed a good safety, tolerability, and acceptability profiles in
HIV patients with serious adverse effect observed in only one among the 124 patients
[148]. The long-acting NPs with a combination of rilpivirine and cabotegravir showed a
prolong HIV-1 inhibition till 96 weeks [149], and a good safety and tolerability profiles
[150].
In our ongoing pilot experiment, we tested the PLGA-EVG NPs in an HIV-1
encephalitis (HIVE) mouse model where HIV-1-ADA-infected MDM were injected
bilaterally into the basal ganglia of NSG humanized mice as described previously [151].
HIVE mouse model has been previously used for studies of HIV-associated
neuroinflammation. The HIVE mouse model is a macrophage/microglia-centric model
that is more appropriate to use in this proposal, and can be used to study the contributions
of HIV-infected human macrophages and/or microglia to HAND [152] PLGA-EVG NPs
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showed a trend of decreasing the CNS HIV-1 gag expression in humanized HIVE mice
model, relative to EVG native drug (Figure 5-1). Due to the limited animal number, we
could not show a significant suppression in the CNS viral load using PLGA-EVG NPs. A
further investigation with a higher number of animals can be conducted in the future to
validate the efficacy of PLGA-EVG NPs in suppressing CNS viral load and improving
cognitive dysfunction in HIV-1-infected humanized mice.
Recently, a new in vivo mouse model which reproduced many important
characteristics of HIV has been developed. Humanized mice with CD34+ hematopoietic
progenitor cell transplanted were infected by HIV-1ADA strain. This CD34+ mice model
represented human microglia-like cells in the mouse brain, that can be used to study CNS
viral reservoir microglia, including CNS HIV-1 viral load and the effects of therapeutic
interventions. In order to move forward, the efficacy of our nanoformulation can also be
validated using this new mouse model to study the neurotoxicity and the effects of
therapeutic interventions in mouse brain [153].
The future direction of this project can also be utilization of monoclonal
antibodies to target delivery of NPs to macrophages and microglia. NPs with specific
recognition ligands bound to the surface have good potential for targeted delivery.
Targeted NPs have shown promise in improvement to cancer therapy alongside
conventional chemotherapy [154]. Based on the studies in cancer therapy, using targeted
NPs to deliver ARVs to viral reservoirs may offer advantages such as increased viral
suppression, and minimized off-target toxicity [155]. The potential receptors for
macrophages targeting can be the CD14 and CD16 receptors. Studies have shown that the
number of CD14+ and CD16+ monocytes were higher in the peripheral blood of HIV-1infected individuals compared with uninfected subjects [156]. CD14+ and CD16+
monocytes are the subset of monocytes that are most permissive to HIV-1 infection, and
preferentially transmigrate across the BBB [157-159]. The potential receptors for
targeting NPs to microglia can be receptors Iba1 and CD68, which are highly expressed
in microglia [160]. Another potential receptor for microglia targeting is transmembrane
protein 119 (TMEM119). Recently, TMEM119 is gaining importance as a specific
marker of microglia, because TMEM119 immunoreactivity was found to be expressed
exclusively on Iba1+ CD68+ microglia in the human brain but not on Iba1+ CD68+
infiltrating macrophages [161]. Therefore, targeting TMEM119 receptor to deliver the
ARVs would be a potential way to suppress the virus specifically in microglia. However,
after coupling with antibodies, PLGA NPs are likely to increase their particle size due to
the large molecular weight of the added antibodies. The alternative way is to use
monocytes or macrophages as endogenous drug carriers to deliver the NPs to the brain.
Studies reported that monocytes and macrophages can cross the BBB under normal
physiological conditions [162]. Previous studies have also attempted to use monocyte and
macrophage-based drug carriers for targeted delivery of nanoformulated ART drugs to
the brain [163, 164]. For example, indinavir NPs which loaded on murine bone marrow
macrophages, showed an increased drug concentration levels and a reduced HIV-1
replication in mouse brain using a HIVE mouse model [163]. Magnetic azidothymidine
NPs loaded on monocytes showed an enhanced trans-endothelial migration compared to
non-monocytes loaded NPs [164].
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Figure 5-1. Viral suppression of EVG and PLGA-EVG in a HIVE mouse model.
Viral suppression of EVG was measured after i.p. administration of 200 mg/kg dose of
vehicle control (PLGA-Blank NPs, n = 2), EVG native drug (n = 2), or PLGA-EVG (n =
2) to HIVE mice. CNS viral load was presented as HIV-gag level and normalized to the
control group, which was injected i.p. with PLGA-Blank NPs, and reported as a
percentage of the control group.
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To further enhance the efficacy of the PLGA-EVG NPs, a commonly used
combination of ARVs such as tenofovir alafenamide and emtricitabine can also be
formulated with EVG into the same formulation to suppress different stages of the HIV-1
life cycle. Formulation of multiple drugs into PLGA NP is practical, and EVG has been
used together with tenofovir alafenamide in a PLGA-based NPs coated with poloxamer
407 as an HIV-1 prevention strategy in a recent report [70]. However, introducing
multiple ARVs to the CNS may also increase the potential of neurotoxicity. An
alternative option is to use the chemodietary agent curcumin as an adjuvant therapy,
which is being used in treating CNS diseases and reducing inflammation and oxidative
stress, which are the hallmark of HIV-1 pathogenesis [165-167]. Curcumin supplement
has been enrolled in 15 clinical phase I/II studies for the therapeutic intervention of
cognitive impairment [167]. Curcumin has been described as an inhibitor of P-gp and
CYP 3A4 [168, 169]. Thus, in addition to its own anti-inflammatory and anti-oxidative
effects, the use of curcumin will also aid in reducing the necessary EVG dose and prevent
EVG-induced neurotoxicity.
Overall, nanotechnology is likely to provide a new approach for delivery of ARV
for the intervention of HAND. Since nanotechnology is a novel delivery method, longterm adverse reactions, systemic toxicities, neurotoxicities, and the accumulation of
nanomaterials in body need to be studied. In order to move forward to the clinical use,
comprehensive toxicity and safety assessments of nanoformulation need to be addressed
including animal studies using non-human primates to demonstrate efficacy, safety, and
dose ranges.
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